(19)
(11)EP 2 802 577 B1

(12)EUROPEAN PATENT SPECIFICATION

(45)Mention of the grant of the patent:
01.03.2017 Bulletin 2017/09

(21)Application number: 13700829.8

(22)Date of filing:  11.01.2013
(51)Int. Cl.: 
C07D 413/04  (2006.01)
C07D 417/04  (2006.01)
C07D 471/04  (2006.01)
A61K 31/437  (2006.01)
A61K 31/444  (2006.01)
A61K 31/496  (2006.01)
A61K 31/498  (2006.01)
A61K 31/506  (2006.01)
C07D 413/14  (2006.01)
C07D 417/14  (2006.01)
C07D 487/04  (2006.01)
A61K 31/4439  (2006.01)
A61K 31/4545  (2006.01)
A61K 31/497  (2006.01)
A61K 31/5025  (2006.01)
(86)International application number:
PCT/US2013/021096
(87)International publication number:
WO 2013/106614 (18.07.2013 Gazette  2013/29)

(54)

TRIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS

TRIAZOLYLSUBSTITUIERTE PYRIDYLVERBINDUNGEN ALS KINASEINHIBITOREN

COMPOSÉS PYRIDYLES À SUBSTITUTION TRIAZOLYLE UTILES COMME INHIBITEURS DE KINASES


(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)Priority: 13.01.2012 US 201261586139 P

(43)Date of publication of application:
19.11.2014 Bulletin 2014/47

(73)Proprietor: Bristol-Myers Squibb Company
Princeton, NJ 08543 (US)

(72)Inventors:
  • DODD, Dharmpal, S.
    Princeton, New Jersey 08543 (US)
  • MUSSARI, Christopher, P.
    New Jersey 08543 (US)
  • BHIDE, Rajeev, S.
    Princeton, New Jersey 08543 (US)
  • NAIR, Satheesh Kesavan
    Bangalore 560 100 (IN)
  • PAIDI, Venkatram Reddy
    Bangalore 560 100 (IN)
  • KUMAR, Sreekantha Ratna
    Bangalore 560 100 (IN)
  • BANERJEE, Abhisek
    West Bengal Pin 711101 (IN)
  • SISTLA, Ramesh
    Bangalore 560 100 (IN)
  • PITTS, William, J.
    Princeton, New Jersey 08543 (US)
  • HYNES, John
    Princeton, New Jersey 08543 (US)

(74)Representative: Vögeli-Lange, Regina et al
Swords Laboratories Swiss Branch, Steinhausen Hinterbergstrasse 16
6330 Cham
6330 Cham (CH)


(56)References cited: : 
WO-A1-2009/044162
WO-A1-2011/006567
WO-A1-2010/007756
  
  • BUCKLEY G M ET AL: "IRAK-4 inhibitors. Part 1: A series of amides", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 18, no. 11, 1 June 2008 (2008-06-01), pages 3211-3214, XP022711199, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2008.04.058 [retrieved on 2008-04-26]
  • BUCKLEY G M ET AL: "IRAK-4 inhibitors. Part II: A structure-based assessment of imidazo[1,2-a]pyridine binding", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 18, no. 11, 1 June 2008 (2008-06-01), pages 3291-3295, XP022711215, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2008.04.039 [retrieved on 2008-04-22]
  • BUCKLEY G M ET AL: "IRAK-4 inhibitors. Part III: A series of imidazo[1,2-a]pyridines", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 18, no. 12, 15 June 2008 (2008-06-15) , pages 3656-3660, XP022707452, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2008.04.042 [retrieved on 2008-04-24]
  
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


Description

FIELD OF THE INVENTION



[0001] This invention relates to compounds useful as kinase inhibitors, including the modulation of IRAK-4. Provided herein are triazole-substituted pyridyl compounds, compositions comprising such compounds, and the compounds for use in methods of treatment. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention that are useful for the treatment of conditions related to kinase modulation and methods of inhibiting the activity of kinases, including IRAK-4 in a mammal.

BACKGROUND OF THE INVENTION



[0002] Toll/IL-1 receptor family members are important regulators of inflammation and host resistance. The Toll like receptor (TLR) family recognizes molecular patterns derived from infectious organisms including bacteria, fungi, parasites, and viruses (reviewed in Kawai, T., et al. 2010, Nature Immunol. 11:373-384). Ligand binding to the receptor induces dimerization and recruitment of adaptor molecules to a conserved cytoplasmic motif in the receptor termed the Toll/IL-1 receptor (TIR) domain. With the exception of TLR3, all TLRs recruit the adaptor molecule MyD88. The IL-1 receptor family also contains a cytoplasmic TIR motif and recruits MyD88 upon ligand binding (reviewed in Sims, J.E., et al. 2010, Nature Rev. Immunol. 10: 89-102).

[0003] Members of the IRAK family of serine/threonine kinases are recruited to the receptor via interactions with MyD88. The family consists of four members. Several lines of evidence indicate that IRAK4 plays a critical and non-redundant role in initiating signaling via MyD88 dependent TLRs and IL-1R family members. Structural data confirms that IRAK4 directly interacts with MyD88 and subsequently recruits either IRAK1 or IRAK2 to the receptor complex to facilitate downstream signaling (Lin, S., et al., 2010, Nature 465: 885-890). IRAK4 directly phosphorylates IRAK1 to facilitate downstream signaling to the E3 ubiquitin ligase TRAF6, resulting in activation of the serine/threonine kinase TAK1 with subsequent activation of the NF kappaB pathway and MAPK cascade (Flannery, S. et al.,. 2010, Biochem. Pharmacol. 80: 1981-1991). A subset of human patients was identified who lack IRAK4 expression (Picard, C. et al., 2003, Science 299: 2076-2079). Cells from these patients fail to respond to all TLR agonists with the exception of TLR3 as well as to members of the IL-1 family including IL-1β and IL-18 (Ku, C.. et al., 2007, J. Exp. Med. 204: 2407-2422). Deletion of IRAK4 in mice results in a severe block in IL-1, IL-18 and all TLR dependent responses with the exception of TLR3 (Suzuki, N. et al., 2002, Nature 416: 750-754). In contrast, deletion of either IRAK1 (Thomas, J.A. et al. 1999, J. Immunol. 163: 978-984; Swantek, J.L. et al., 2000, J. Immunol. 164: 4301-4306) or IRAK2 (Wan, Y. et al., 2009, J. Biol. Chem. 284: 10367-10375) results in partial loss of signaling. Furthermore, IRAK4 is the only member of the IRAK family whose kinase activity has been shown to be required for initiation of signaling. Replacement of wild type IRAK4 in the mouse genome with a kinase inactive mutant (KDKI) impairs signaling via all MyD88 dependent receptors including IL-1, IL-18 and all TLRs with the exception of TLR3 (Koziczak-Holbro, M. et al., 2007, J. Biol. Chem. 282: 13552-13560; Kawagoe, T et al., 2007, J. Exp. Med. 204: 1013-1024; and Fraczek, J. et al., 2008, J. Biol. Chem. 283: 31697-31705).

[0004] As compared to wild type animals, IRAK4 KDKI mice show greatly reduced disease severity in mouse models of multiple sclerosis (Staschke, K.A. et al., 2009, J. Immunol. 183: 568-577), rheumatoid arthritis (Koziczak-Holbro, M. et al., 2009, Arthritis Rheum. 60: 1661-1671), atherosclerosis(Kim, T.W. et al., 2011, J. Immunol.186: 2871-2880 and Rekhter, M. et al., 2008, Bioch. Bioph. Res. Comm. 367: 642-648), and myocardial infarction (Maekawa, Y., et al., 2009 Circulation 120: 1401-1414). As described, IRAK4 inhibitors will block all MyD88 dependent signaling. MyD88 dependent TLRs have been shown to contribute to the pathogenesis of multiple sclerosis, rheumatoid arthritis, cardiovascular disease, metabolic syndrome, sepsis, systemic lupus erythematosus, inflammatory bowel diseases including Crohn's disease and Ulcerative colitis, autoimmune uveitis, asthma, allergy, type I diabetes, and allograft rejection (Keogh, B. et al., 2011, Trends Pharmacol. Sci. 32: 435-442; Mann, D.L. 2011, Circ. Res. 108: 1133-1145; Horton, C.G. et al., 2010, Med. Inflamm. Pii. 498980; Goldstein, D.R. et al., 2005, J. Heart Lung Transpl. 24: 1721-1729; and Cario, E., 2010, Inflamm. Bowel Dis. 16: 1583-1597). Oncogenically active MyD88 mutations in diffuse large B cell lymphomas have been identified that are sensitive to IRAK4 inhibition (Ngo, VN et al., 2011, Nature 470: 115-121). Whole genome sequencing also identified mutations in MyD88 associated with chronic lymphatic leukemia suggesting that IRAK4 inhibitors may also have utility in treating leukemias (Puente, X.S. et al., 2011, Nature 475: 101-105).

[0005] In addition to blocking TLR signaling, IRAK4 inhibitors will also block signaling by members of the IL-1 family. Neutralization of IL-1 has been shown to be efficacious in multiple diseases including gout; gouty arthritis; type 2 diabetes; autoinflammatory diseases including CAPS, TRAPS, FMF, adult onset stills; systemic onset juvenile idiopathic arthritis; stroke; GVHD; smoldering multiple myeloma; recurrent pericarditis; osteoarthritis; emphysema (Dinarello, C.A., 2011, Eur. J. Immunol. 41: 1203-1217 and Couillin, I. et al., 2009. J. Immunol. 183: 8195-8202). In a mouse model of Alzheimer's disease, blockade of IL-1 receptor improved cognitive defects, attenuated tau pathology and reduced oligomeric forms of amyloid-β (Kitazawa, M. et al., 2011, J. Immunol. 187: 6539-6549). IL-1 has also been shown to be a critical link to adaptive immunity, driving differentiation of the TH17 effector T cell subset (Chung, Y., Chang, S.H. et al., 2009, Immunity 30: 576-587). Therefore, IRAK4 inhibitors are predicted to have efficacy in TH17 associated diseases including multiple sclerosis, psoriasis, inflammatory bowel diseases, autoimmune uveitis, and rheumatoid arthritis (Wilke, C.M., et al., 2011, Trends Immunol. 32: 603-61).

[0006] In view of the conditions that may benefit by treatment involving modulation of protein kinases, it is immediately apparent that new compounds capable of modulating protein kinases such as IRAK-4 and methods of using these compounds could provide substantial therapeutic benefits to a wide variety of patients.

[0007] WO 2011/006567 describes aminopyridine derivatives comprising a 2-amino 3-benzimidazole (or imidazole-based bicyclic heteroaryl)-4-heteroaryl pyridine for the control or treatment of tumors, tumor growth and tumor metastases and inflammatory diseases. Buckley et al (Bioorganic & Medicinal Chemisty Letters, Pergamon, Elsevier Science, GB, vol.18, no. 11, June 2008, pages 3211-3214 and pages 3291-3295; vol. 18, no. 12, June 2008, pages 3656-3660) describe the potency of a series of amides and imidazo[1,2-a]pyridines as IRAK-4 inhibitors.

[0008] The present invention relates to a new class of triazole-substituted pyridyl compounds found to be effective inhibitors of protein kinases including IRAK-4.

SUMMARY OF THE INVENTION



[0009] Modulators of kinase activity which may generally be described as triazole-substituted pyridyl compounds found are provided herein.

[0010] The invention is directed to compounds of Formula I that which are useful as inhibitors of IRAK-4, and are useful for the treatment of proliferative diseases, allergic diseases, autoimmune diseases and inflammatory diseases, or stereoisomers, tautomers, pharmaceutically acceptable slats, or solvates thereof.

[0011] The present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, thereof.

[0012] A preferred embodiment is the compounds of the invention for use in treating inflammatory and autoimmune diseases wherein the treatment of inflammatory diseases is even more preferred. Particular, inflammatory and autoimmune diseases include, but are not limited to, Crohn's, ulcerative colitis, asthma, graft versus host disease, allograft rejection, chronic obstructive pulmonary disease; Graves' disease, rheumatoid arthritis, systemic lupus erythematosis, psoriasis; CAPS, TRAPS, FMF, adult onset stills, systemic onset juvenile idiopathic arthritis, multiple sclerosis, neuropathic pain, gout, and gouty arthritis.

[0013] These and other features of the invention will be set forth in the expanded form as the disclosure continues.

DETAILED DESCRIPTION OF THE EMBODIMENTS OF THE INVENTION



[0014] Provided herein is at least one chemical entity chosen from compounds of formula (I):

or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein:

A is a triazole optionally substituted by 0-2 R;

R is hydrogen, R1, halogen, cyano, nitro, -OR1, -C(=O)-R1, -C(=O)O- R1, -C(=O)NR11-R1, -S(=O)2-R1, -NR11C(=O)- R1, -NR11C(=O)NR11R1, -NR11C(=O)O- R1, -NR11S(=O)2R1 or -NR11R1;

R1 is C1-6 alkyl substituted with 0-4 R1a, C1-6 haloalkyl, C2-6 alkenyl substituted with 0-3 R1a, C2-6 alkynyl substituted with 0-3 R1a, C3-10 cycloalkyl substituted with 0-3 R1a, C6-10 aryl substituted with 0-3 R1a, a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R1a, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R1a;

R1a is hydrogen, =O, F, Cl, Br, OCF3, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyl substituted with 0-2 Ra, C1-6 haloalkyl, -(CH2)r-3-14 membered carbocycle substituted with 0-3 Ra, or -(CH2)r-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-3 Ra;

R2 is C6-10 aryl substituted with 0-4 R2a, a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, substituted with 1-4 R2a, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-4 R2a;

R2a at each occurrence is independently selected from hydrogen, =O, halo, OCF3, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyl substituted with 0-2 Ra, C1-6 haloalkyl, -(CH2)r-3-14 membered carbocycle substituted with 0-1 Ra, or -(CH2)r-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-2 Ra;

R3 is C1-6 alkyl substituted with 0-3 R3a, C1-6 haloalkyl, C2-6 alkenyl substituted with 0-3 R3a, C2-6 alkynyl substituted with 0-3 R3a, C3-10 cycloalkyl substituted with 0-3 R3a, C6-10 aryl substituted with 0-3 R3a, a 5-10 membered heterocyclyl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R3a or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R3a;

R3a is hydrogen, =O, F, Cl, Br, OCF3, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyl substituted with 0-2 Ra, C1-6haloalkyl, -(CH2)r-3-14 membered carbocycle substituted with 0-1 Ra, or -(CH2)r-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-1 Ra;

R4 and R5 are independently selected from hydrogen, C1-4 alkyl substituted with 0-1 Rf, (CH2)-phenyl substituted with 0-3 Rd, and a -(CH2)-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p,;

R6 is selected from hydrogen, =O, F, Cl, Br, OCF3, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyl substituted with 0-2 Ra, C1-6haloalkyl, -(CH2)r-3-14 membered carbocycle substituted with 0-3 Ra, or -(CH2)r-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-3 Ra;

R11 at each occurrence is independently hydrogen, Re, C1-4 alkyl substituted with 0-1 Rf, CH2-phenyl substituted with 0-3 Rd, or -(CH2)-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-3 Rd; or

R11 and along with another R11, R1, or R2 on the same nitrogen atom may join to form an optionally substituted heterocycle;

Ra is hydrogen, F, Cl, Br, OCF3, CF3, CHF2, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyl substituted with 0-1 Rf, C1-6 haloalkyl, -(CH2)r-3-14 membered carbocycle, or -(CH2)r-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p; or two Ra on adjacent or the same carbon atom form a cyclic acetal of the formula -O-(CH2)n-O-, or -O-CF2-O-, wherein n is selected from 1 or 2;

Rb is hydrogen, Re, C1-6 alkyl substituted with 0-2 Rd, C1-6 haloalkyl, C3-6 cycloalkyl substituted with 0-2 Rd, or (CH2)r-phenyl substituted with 0-3 Rd;

Rc is C1-6 alkyl substituted with 0-1 Rf, C3-6 cycloalkyl, or (CH2)r-phenyl substituted with 0-3 Rf;

Rd is hydrogen, F, Cl, Br, OCF3, CF3, CN, NO2, -ORe, -(CH2)rC(O)Rc, -NReRe, -NReC(O)ORc, C1-6 alkyl, or (CH2)r-phenyl substituted with 0-3 Rf;

Re is selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r-phenyl substituted with 0-3 Rf;

Rf is hydrogen, halo, NH2, OH, or O(C1-6alkyl);

p is 0, 1, or 2;

r is 0, 1, 2, 3, or 4; and

m is 0, 1, or 2.



[0015] In another embodiment, there are provided compounds of formula I wherein A is

and X1 and X2 are independently selected from N or C-R, provided that one of X1 and X2 is N and the other is C-R.

[0016] In another embodiment, there is provided a compound of formula I, R2 is phenyl, pyridyl, pyrimidinyl, naphthyl, indolinyl, benzothiazolyl, pyrazolopyridinyl, benzoisothiazolyl, triazolopyridinyl, imidazopyridinyl, benzooxazolyl, triazolopyridinyl, imidazopyridinyl, pyridopyrazinyl, quinazolinyl, pyridopyrazinyl, benzooxadiazolyl, benzothiadiazolyl, benzoimidazolyl, triazolopyridinyl, imdazopyridazinyl, pyridopyrazinyl, naphthyridinyl, quinoxalinyl, phthalazinyl, quinolinyl, indolyl, benzothiazolyl, benzodioxolyl, benzothienyl, isoquinolinyl, benzopyranyl, indolizinyl, benzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, pyrrolopyridyl, furopyridyl, isoindolyl, or quinazolinyl, each group substituted by 1-4 groups selected from R2a.

[0017] In another embodiment, there is provided a compound of formula I, wherein m is 0.

[0018] In another embodiment, there is provided a compound of formula I, wherein wherein both R4 and R5 are hydrogen.

[0019] In another embodiment, there is provided a compound having the formula:

or a stereoisomer or pharmaceutically salt thereof, wherein:

X1 and X2 are independently selected from N or C-R, provided one of X1 and X2 is selected from N and the other from C-R;

R is hydrogen, R1, halogen,-C(=O)-R1, -C(=O)OR1, -C(=O)NR11R1 or -NR11R1;

R1 is C1-6 alkyl substituted with 0-4 R1a, C1-6haloalkyl, C2-6 alkenyl substituted with 0-3 R1a, C2-6 alkynyl substituted with 0-3 R1a, C3-10 cycloalkyl substituted with 0-3 R1a, C6-10 aryl substituted with 0-3 R1a, a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R1a, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R1a;

R1a is hydrogen, =O, F, Cl, Br, OCF3, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6alkyl substituted with 0-2 Ra, C1-6haloalkyl, -(CH2)r-3-14 membered carbocycle substituted with 0-1 Ra, or -(CH2)r-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-1 Ra;

R2 is phenyl, pyridyl, pyrimidinyl, naphthyl, indolinyl, benzothiazolyl, pyrazolopyridinyl, benzoisothiazolyl, triazolopyridinyl, imidazopyridinyl, benzooxazolyl, triazolopyridinyl, imidazopyridinyl, pyridopyrazinyl, quinazolinyl, pyridopyrazinyl, benzooxadiazolyl, benzothiadiazolyl, benzoimidazolyl, triazolopyridinyl, imdazopyridazinyl, pyridopyrazinyl, naphthyridinyl, quinoxalinyl, phthalazinyl, quinolinyl, indolyl, benzothiazolyl, benzodioxolyl, benzothienyl, isoquinolinyl, benzopyranyl, indolizinyl, benzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, pyrrolopyridyl, furopyridyl, isoindolyl, or quinazolinyl each group substituted by 1-4 groups selected from R2a;

R2a is hydrogen, =O, F, Cl, Br, OCF3, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyl substituted with 0-2 Ra, C1-6haloalkyl, -(CH2)r-3-14 membered carbocycle substituted with 0-1 Ra, or -(CH2)r-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-1 Ra;

R3 is C1-6 alkyl substituted with 0-3 R3a; or a C3-7cycloalkyl, phenyl, tetrahydropyranyl, tetrahydrofuranyl, or oxetane ring, each ring optionally substituted with 0-3 R3a;

R3a is hydrogen, =O, F, Cl, Br, OCF3, CF3, CHF2, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyl substituted with 0-2 Ra, C1-6 haloalkyl, -(CH2)r-3-14 membered carbocycle substituted with 0-1 Ra, or -(CH2)r-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-1 Ra;

R11 at each occurrence is independently hydrogen, C1-4 alkyl substituted with 0-1 Rf, CH2-phenyl substituted with 0-3 Rd, or -(CH2)-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-3 Rd;

Ra is hydrogen, Cl, Br, OCF3, CF3, CHF2, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyl, C1-6 haloalkyl, -(CH2)r-3-14 membered carbocycle, or -(CH2)r-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p, alternatively two Ra on adjacent or the same carbon atom form a cyclic acetal of the formula -O-(CH2)n-O-, or -O-CF2-O-, wherein n is selected from 1 or 2;

Rb is hydrogen, C1-6 alkyl substituted with 0-2 Rd, C1-6 haloalkyl, C3-6 cycloalkyl substituted with 0-2 Rd, or (CH2)r-phenyl substituted with 0-3 Rd;

Rc is C1-6 alkyl, C3-6 cycloalkyl, or (CH2)r-phenyl substituted with 0-3 Rf;

Rd is hydrogen, F, Cl, Br, OCF3, CF3, CN, NO2, -ORe, -(CH2)rC(O)Re, -NReRe, -NReC(O)ORc, C1-6 alkyl, or (CH2)r-phenyl substituted with 0-3 Rf;

Re is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, or (CH2)r-phenyl substituted with 0-3 Rf;

Rf is hydrogen, halo, NH2, OH, or O(C1-6alkyl);

r is 0, 1, 2, 3, or 4; and

p is 0, 1, or 2.



[0020] In another embodiment, there is provided a compound wherein R2 is selected













each group substituted by 0-4 R2a. Bicyclic R2a are more preferred.

[0021] In a preferred embodiment, there is provided a compound wherein R2a is selected from hydrogen, =O, CONH2, C1-6alkyl, halo, -OC1-6alkyl, C(O)O C1-6alkyl, C(O)NHC1-6alkyl, CN, C1-6haloalkyl, NH2, NHC1-6alkyl, N(C1-6alkyl)2, OH, and an optionally substituted 5-6 membered heterocycle or heteroaryl, each having 1-3 ring atoms selected from O, N or S.

[0022] In a more preferred embodiment compounds are provided wherein R2a is independently selected from 1-4 groups at each occurrence from fluoro, chloro, =O, -OH, OMe, hydrogen, CO2Et, CONHMe, CN, CF3, NH2, OH, CN, CONH2, pyridyl, morpholinyl, and oxazolyl.

[0023] In yet another more preferred embodiment compounds are provided wherein R2 is selected from

and

each group optionally substituted by 0-3 R2a.

[0024] In another more preferred embodiment, there is provided a compound of formula I, wherein R2 is selected from



[0025] In an alternate more preferred embodiment, there is provided a compound of formula I, wherein R2 is

andY is Cl, F, Br, CN, -OC1-6alkyl, C1-6alkyl,-haloC1-6alkyl, or NH2 (especially Cl, F or CN).

[0026] In a more preferred embodiment there are provided compounds in which R is selected from the following:





























[0027] In yet another embodiment there is provided a compound wherein R3 is C1-6 alkyl substituted with 0-3 R3a or phenyl optionally substituted with 0-3 R3a. A more preferred R3 is i-pr.

[0028] In another preferred embodiment, there is provided a compound of formula I, wherein R3 is selected from C1-6 alkyl (especially preferred is i-Pr).

[0029] In another embodiment, there is provided a pharmaceutical composition comprising one or more compounds of formula I and a pharmaceutically acceptable carrier or diluent.

[0030] The present invention also discloses pharmaceutical compositions useful in treating diseases associated with kinase modulation, including modulation (especially inhibition) of IRAK-4, comprising compounds of formula (I), or pharmaceutically-acceptable salts thereof, and pharmaceutically-acceptable carriers or diluents.

[0031] The present invention also discloses processes and intermediates for making the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof.

[0032] The present invention also provides the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, use for the treatment of proliferative, metabolic, allergic, autoimmune and inflammatory diseases, comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof.

[0033] The present invention also provides the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, use for the treatment of these diseases, comprising administering to a patient in need of such treatment a therapeutically-effective amount of a compound of formula I, wherein the disease is Crohn's, ulcerative colitis, asthma, graft versus host disease, allograft rejection, chronic obstructive pulmonary disease; Graves' disease, rheumatoid arthritis, systemic lupus erythematosis, psoriasis; CAPS, TRAPS, FMF, adult onset stills, systemic onset juvenile idiopathic arthritis, multiple sclerosis, neuropathic pain, gout, and gouty arthritis.

[0034] The present invention also provides the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, for the treatment of these diseases wherein the disease is selected from type 2 diabetes and atherosclerosis.

[0035] In addition, the present invention also provides the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, use for the treatment of these conditions comprising administering to a patient in need of such treatment a therapeutically-effective amount of a compound of formula I, wherein the condition is selected from acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, solid tumors, ocular neovasculization, and infantile haemangiomas, B cell lymphoma, systemic lupus erythematosus (SLE), rheumatoid arthritis, psoriatic arthritis, multiple vasculitides, idiopathic thrombocytopenic purpura (ITP), myasthenia gravis, allergic rhinitis, multiple sclerosis (MS), transplant rejection, Type I diabetes, membranous nephritis, inflammatory bowel disease, autoimmune hemolytic anemia, autoimmune thyroiditis, cold and warm agglutinin diseases, Evan's syndrome, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP), sarcoidosis, Sjögren's syndrome, peripheral neuropathies, pemphigus vulgaris and asthma.

[0036] The present invention also provides the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, use for the treatment of rheumatoid arthritis, comprising administering to a patient in need of such treatment a therapeutically-effective amount of a compound of formula I.

[0037] The present invention also discloses a method of treating a TLR/IL-1 mediated disease (or use of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, for the manufacture of a medicament for the treatment of these diseases), comprising administering to a patient in need of such treatment a therapeutically-effective amount of a compound of formula I

[0038] The present invention also discloses a method of treating a TLR/IL-1 mediated disease (or use of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, for the manufacture of a medicament for the treatment of these diseases), comprising administering to a patient in need of such treatment a therapeutically-effective amount of a compound of formula I, wherein the TLR/IL-1 mediated disease is a disease modulated by a kinase selected from IRAK-4.

[0039] The present invention also discloses a method of treating diseases, comprising administering to a patient in need of such treatment a therapeutically-effective amount of a compound of formula I, or pharmaceutically acceptable salt thereof, in combination with other therapeutic agents.

[0040] The present invention also provides the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, for use in therapy.

[0041] In another embodiment, compounds of formula I are selected from exemplified compounds or combinations of exemplified compounds or other embodiments herein.

[0042] In another embodiment, the present invention is directed to a pharmaceutical composition comprising a compound of formula (I) and one or more active ingredients.

[0043] The present invention further discloses a method for modulation of chemokine or chemokine receptor activity comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprised of a compound of formula (I) and one or more active ingredients.

[0044] The present invention also discloses a method for modulation of IRAK-4 receptor activity comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprised of a compound of formula (I) and one or more active ingredients.

[0045] In another embodiment are compounds having an IC50 < 1000 nM in the IRAK-4 assay described below.

[0046] This invention encompasses all combinations of preferred aspects and/or embodiments of the invention noted herein. It is understood that any and all embodiments of the present invention may be taken in conjunction with any other embodiment or embodiments to describe additional more preferred embodiments. It is also to be understood that each individual element of the preferred embodiments is its own independent preferred embodiment. Furthermore, any element of an embodiment is meant to be combined with any and all other elements from any embodiment to describe an additional embodiment.

DETAILED DESCRIPTION OF THE INVENTION



[0047] The following are definitions of terms used in this specification and appended claims. The initial definition provided for a group or term herein applies to that group or term throughout the specification and claims, individually or as part of another group, unless otherwise indicated.

[0048] Compounds of this invention may have one or more asymmetric centers. Unless otherwise indicated, all chiral (enantiomeric and diastereomeric) and racemic forms of compounds of the present invention are included in the present invention. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. The present compounds can be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. All chiral, (enantiomeric and diastereomeric) and racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomer form is specifically indicated.

[0049] When any variable (e.g., R3) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R3, then said group may optionally be substituted with up to two R3 groups and R3 at each occurrence is selected independently from the definition of R3. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

[0050] When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

[0051] In cases wherein there are nitrogen atoms (e.g., amines) on compounds of the present invention, these can be converted to N-oxides by treatment with an oxidizing agent (e.g., MCPBA and/or hydrogen peroxides) to afford other compounds of this invention. Thus, all shown and claimed nitrogen atoms are considered to cover both the shown nitrogen and its N-oxide (N→O) derivative.

[0052] In accordance with a convention used in the art,

is used in structural formulas herein to depict the bond that is the point of attachment of the moiety or substituent to the core or backbone structure.

[0053] A dash "-" that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -CONH2 is attached through the carbon atom.

[0054] The term "optionally substituted" in reference to a particular moiety of the compound of Formula I (e.g., an optionally substituted heteroaryl group) refers to a moiety having 0, 1, 2, or more substituents. For example, "optionally substituted alkyl" encompasses both "alkyl" and "substituted alkyl" as defined below. It will be understood by those skilled in the art, with respect to any group containing one or more substituents, that such groups are not intended to introduce any substitution or substitution patterns that are sterically impractical, synthetically non-feasible and/or inherently unstable.

[0055] As used herein, the term "at least one chemical entity" is interchangeable with the term "a compound."

[0056] As used herein, the term "alkyl" or "alkylene" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. For example, "C1-10 alkyl" (or alkylene), is intended to include C1, C2, C3, C4, C5, C6, C7, C8, C9, and C10 alkyl groups. Additionally, for example, "C1-C6 alkyl" denotes alkyl having 1 to 6 carbon atoms. Alkyl groups can be unsubstituted or substituted so that one or more of its hydrogens are replaced by another chemical group. Example alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, t-butyl), pentyl (e.g., n-pentyl, isopentyl, neopentyl), and the like.

[0057] Alkenyl" or "alkenylene" is intended to include hydrocarbon chains of either straight or branched configuration and having one or more double carbon-carbon bonds that may occur in any stable point along the chain. For example,
"C2-6 alkenyl" (or alkenylene), is intended to include C2, C3, C4, C5, and C6 alkenyl groups. Examples of alkenyl include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3, pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl, 4-methyl-3-pentenyl, and the like.

[0058] "Alkynyl" or "alkynylene" is intended to include hydrocarbon chains of either straight or branched configuration and having one or more triple carbon-carbon bonds that may occur in any stable point along the chain. For example, "C2-6 alkynyl" (or alkynylene), is intended to include C2, C3, C4, C5, and C6 alkynyl groups; such as ethynyl, propynyl, butynyl, pentynyl, hexynyl and the like.

[0059] One skilled in the field will understand that, when the designation "CO2" is used herein, this is intended to refer to the group



[0060] When the term "alkyl" is used together with another group, such as in "arylalkyl", this conjunction defines with more specificity at least one of the substituents that the substituted alkyl will contain. For example, "arylalkyl" refers to a substituted alkyl group as defined above where at least one of the substituents is an aryl, such as benzyl. Thus, the term aryl(C0-4)alkyl includes a substituted lower alkyl having at least one aryl substituent and also includes an aryl directly bonded to another group, i.e., aryl(C0)alkyl. The term "heteroarylalkyl" refers to a substituted alkyl group as defined above where at least one of the substituents is a heteroaryl.

[0061] When reference is made to a substituted alkenyl, alkynyl, alkylene, alkenylene, or alkynylene group, these groups are substituted with one to three substituents as defined above for substituted alkyl groups.

[0062] The term "alkoxy" refers to an oxygen atom substituted by alkyl or substituted alkyl, as defined herein. For example, the term "alkoxy" includes the group -O-C1-6alkyl such as methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, 2-pentyloxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, 3-methylpentoxy, and the like. "Lower alkoxy" refers to alkoxy groups having one to four carbons.

[0063] It should be understood that the selections for all groups, including for example, alkoxy, thioalkyl, and aminoalkyl, will be made by one skilled in the field to provide stable compounds.

[0064] The term "substituted", as used herein, means that any one or more hydrogens on the designated atom or group is replaced with a selection from the indicated group, provided that the designated atom's normal valence is not exceeded. When a substituent is oxo, or keto, (i.e., =O) then 2 hydrogens on the atom are replaced. Keto substituents are not present on aromatic moieties. Unless otherwise specified, substituents are named into the core structure. For example, it is to be understood that when (cycloalkyl)alkyl is listed as a possible substituent, the point of attachment of this substituent to the core structure is in the alkyl portion. Ring double bonds, as used herein, are double bonds that are formed between two adjacent ring atoms (e.g., C=C, C=N, or N=N).

[0065] Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds or useful synthetic intermediates. A stable compound or stable structure is meant to imply a compound that is sufficiently robust to survive isolation from a reaction mixture to a useful degree of purity, and subsequent formulation into an efficacious therapeutic agent. It is preferred that the presently recited compounds do not contain a N-halo, S(O)2H, or S(O)H group.

[0066] The term "cycloalkyl" refers to cyclized alkyl groups, including mono-, bi- or poly-cyclic ring systems. C3-7 cycloalkyl is intended to include C3, C4, C5, C6, and C7 cycloalkyl groups. Example cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl, and the like. As used herein, "carbocycle" or "carbocyclic residue" is intended to mean any stable 3, 4, 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, 10, 11, 12, or 13-membered bicyclic or tricyclic ring, any of which may be saturated, partially unsaturated, unsaturated or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptenyl, cycloheptyl, cycloheptenyl, adamantyl, cyclooctyl, cyclooctenyl, cyclooctadienyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane, [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, anthracenyl, and tetrahydronaphthyl (tetralin). As shown above, bridged rings are also included in the definition of carbocycle (e.g., [2.2.2]bicyclooctane). Preferred carbocycles, unless otherwise specified, are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and phenyl. When the term "carbocycle" is used, it is intended to include "aryl". A bridged ring occurs when one or more carbon atoms link two non-adjacent carbon atoms. Preferred bridges are one or two carbon atoms. It is noted that a bridge always converts a monocyclic ring into a bicyclic ring. When a ring is bridged, the substituents recited for the ring may also be present on the bridge.

[0067] The term "aryl" refers to monocyclic or bicyclic aromatic hydrocarbon groups having 6 to 12 carbon atoms in the ring portion, such as phenyl, and naphthyl groups, each of which may be substituted.

[0068] Accordingly, in compounds of formula (I), the term "cycloalkyl" includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclooctyl, etc., as well as the following ring systems,





and the like. Preferred cycloalkyl groups include cyclopropyl, cyclopentyl, cyclohexyl, and



[0069] The term "halo" or "halogen" refers to chloro, bromo, fluoro and iodo.

[0070] The term "haloalkyl" means a substituted alkyl having one or more halo substituents. For example, "haloalkyl" includes mono, bi, and trifluoromethyl.

[0071] The term "haloalkoxy" means an alkoxy group having one or more halo substituents. For example, "haloalkoxy" includes OCF3.

[0072] Thus, examples of aryl groups include:





(fluorenyl) and the like, which optionally may be substituted at any available carbon or nitrogen atom. A preferred aryl group is optionally-substituted phenyl.

[0073] The terms "heterocycloalkyl", "heterocycle", "heterocyclo", "heterocyclic", or "heterocyclyl" may be used interchangeably and refer to substituted and unsubstituted non-aromatic 3-to 7-membered monocyclic groups, 7-to 11-membered bicyclic groups, and 10-to 15-membered tricyclic groups, in which at least one of the rings has at least one heteroatom (O, S or N), said heteroatom containing ring preferably having 1, 2, or 3 heteroatoms selected from O, S, and N. Each ring of such a group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less, and further provided that the ring contains at least one carbon atom. The nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized. The fused rings completing the bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated. The heterocyclo group may be attached at any available nitrogen or carbon atom. The term "heterocycle" includes "heteroaryl" groups. As valence allows, if said further ring is cycloalkyl or heterocyclo it is additionally optionally substituted with =O (oxo).

[0074] Exemplary monocyclic heterocyclyl groups include azetidinyl, pyrrolidinyl, oxetanyl, imidazolinyl, oxazolidinyl, isoxazolinyl, thiazolidinyl, isothiazolidinyl, tetrahydrofuranyl, piperidyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, 1-pyridonyl, 4-piperidonyl, tetrahydropyranyl, morpholinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 1,3-dioxolane and tetrahydro-1,1-dioxothienyl and the like. Exemplary bicyclic heterocyclo groups include quinuclidinyl. Additional monocyclic heterocyclyl groups include



[0075] The term "heteroaryl" refers to substituted and unsubstituted aromatic 5- or 6-membered monocyclic groups, 9- or 10-membered bicyclic groups, and 11- to 14-membered tricyclic groups which have at least one heteroatom (O, S or N) in at least one of the rings, said heteroatom-containing ring preferably having 1, 2, or 3 heteroatoms selected from O, S, and N. Each ring of the heteroaryl group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom. The fused rings completing the bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated. The nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized. Heteroaryl groups which are bicyclic or tricyclic must include at least one fully aromatic ring but the other fused ring or rings may be aromatic or non-aromatic. The heteroaryl group may be attached at any available nitrogen or carbon atom of any ring. As valence allows, if said further ring is cycloalkyl or heterocyclo it is additionally optionally substituted with =O (oxo).

[0076] Exemplary monocyclic heteroaryl groups include pyrrolyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thienyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl and the like.

[0077] Exemplary bicyclic heteroaryl groups include indolyl, benzothiazolyl, benzodioxolyl, benzoxazolyl, benzothienyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridyl, dihydroisoindolyl, tetrahydroquinolinyl and the like.

[0078] Exemplary tricyclic heteroaryl groups include carbazolyl, benzindolyl, phenanthrollinyl, acridinyl, phenanthridinyl, xanthenyl and the like.

[0079] In compounds of formula (I), preferred heteroaryl groups include





and the like, which optionally may be substituted at any available carbon or nitrogen atom.

[0080] Unless otherwise indicated, when reference is made to a specifically-named aryl (e.g., phenyl), cycloalkyl (e.g., cyclohexyl), heterocyclo (e.g., pyrrolidinyl, piperidinyl, and morpholinyl) or heteroaryl (e.g., tetrazolyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, and furyl) the reference is intended to include rings having 0 to 3, preferably 0-2, substituents selected from those recited above for the aryl, cycloalkyl, heterocyclo and/or heteroaryl groups, as appropriate.

[0081] The term "carbocyclyl" or "carbocyclic" refers to a saturated or unsaturated monocyclic or bicyclic ring in which all atoms of all rings are carbon. Thus, the term includes cycloalkyl and aryl rings. Monocyclic carbocycles have 3 to 6 ring atoms, still more typically 5 or 6 ring atoms. Bicyclic carbocycles have 7 to 12 ring atoms, e.g., arranged as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms arranged as a bicyclo [5,6] or [6,6] system. Examples of mono- and bicyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, phenyl and naphthyl. The carbocyclic ring may be substituted in which case the substituents are selected from those recited above for cycloalkyl and aryl groups.

[0082] The term "heteroatoms" shall include oxygen, sulfur and nitrogen.

[0083] When the term "unsaturated" is used herein to refer to a ring or group, the ring or group may be fully unsaturated or partially unsaturated.

[0084] Throughout the specification, groups and substituents thereof may be chosen by one skilled in the field to provide stable moieties and compounds and compounds useful as pharmaceutically-acceptable compounds and/or intermediate compounds useful in making pharmaceutically-acceptable compounds.

[0085] The compounds of formula (I) may exist in a free form (with no ionization) or can form salts which are also within the scope of this invention. Unless otherwise indicated, reference to an inventive compound is understood to include reference to the free form and to salts thereof. The term "salt(s)" denotes acidic and/or basic salts formed with inorganic and/or organic acids and bases. In addition, the term "salt(s) may include zwitterions (inner salts), e.g., when a compound of formula (I), contains both a basic moiety, such as an amine or a pyridine or imidazole ring, and an acidic moiety, such as a carboxylic acid. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, such as, for example, acceptable metal and amine salts in which the cation does not contribute significantly to the toxicity or biological activity of the salt. However, other salts may be useful, e.g., in isolation or purification steps which may be employed during preparation, and thus, are contemplated within the scope of the invention. Salts of the compounds of the formula (I) may be formed, for example, by reacting a compound of the formula (I) with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.

[0086] Exemplary acid addition salts include acetates (such as those formed with acetic acid or trihaloacetic acid, for example, trifluoroacetic acid), adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides (formed with hydrochloric acid), hydrobromides (formed with hydrogen bromide), hydroiodides, 2-hydroxyethanesulfonates, lactates, maleates (formed with maleic acid), methanesulfonates (formed with methanesulfonic acid), 2-naphthalenesulfonates, nicotinates, nitrates, oxalates, pectinates, persulfates, 3-phenylpropionates, phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates (such as those formed with sulfuric acid), sulfonates (such as those mentioned herein), tartrates, thiocyanates, toluenesulfonates such as tosylates, undecanoates, and the like.

[0087] Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts; alkaline earth metal salts such as calcium and magnesium salts; barium, zinc, and aluminum salts; salts with organic bases (for example, organic amines) such as trialkylamines such as triethylamine, procaine, dibenzylamine, N-benzyl-β-phenethylamine, 1-ephenamine, N,N'-dibenzylethylene-diamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, dicyclohexylamine or similar pharmaceutically acceptable amines and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g., decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and others. Preferred salts include monohydrochloride, hydrogensulfate, methanesulfonate, phosphate or nitrate salts.

[0088] The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

[0089] As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic groups such as amines; and alkali or organic salts of acidic groups such as carboxylic acids. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, and isethionic, and the like.

[0090] The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Company, Easton, PA, 1990.

[0091] All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form. Stereoisomers may include compounds which are optical isomers through possession of one or more chiral atoms, as well as compounds which are optical isomers by virtue of limited rotation about one or more bonds (atropisomers). The definition of compounds according to the invention embraces all the possible stereoisomers and their mixtures. It very particularly embraces the racemic forms and the isolated optical isomers having the specified activity. The racemic forms can be resolved by physical methods, such as, for example, fractional crystallization, separation or crystallization of diastereomeric derivatives or separation by chiral column chromatography. The individual optical isomers can be obtained from the racemates from the conventional methods, such as, for example, salt formation with an optically active acid followed by crystallization.

[0092] The present invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include 13C and 14C. Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.

V.



[0093] Compounds of the formula (I) and salts thereof may exist in their tautomeric form, in which hydrogen atoms are transposed to other parts of the molecules and the chemical bonds between the atoms of the molecules are consequently rearranged. It should be understood that the all tautomeric forms, insofar as they may exist, are included within the invention. Additionally, inventive compounds may have trans and cis isomers,

[0094] It should further be understood that solvates (e.g., hydrates) of the compounds of Formula (I) are also with the scope of the present invention. Methods of solvation are generally known in the art.

UTILITY



[0095] The compounds of the invention modulate kinase activity, including the modulation of IRAK-4. Other types of kinase activity that may be modulated by the compounds of the instant invention include, but are not limited to, the Pelle/IRAK family and mutants thereof.

[0096] Accordingly, compounds of formula (I) have utility in treating conditions associated with the modulation of kinase activity, and particularly the selective inhibition of IRAK-4 activity or the inhibition of IRAK and other Pelle family kinases. Such conditions include TLR/IL-1family receptor associated diseases in which cytokine levels are modulated as a consequence of intracellular signaling. Moreover, the compounds of formula (I) have advantageous selectivity for IRAK-4 activity, preferably from at least 20 fold to over 1,000 fold more selective.

[0097] As used herein, the terms "treating" or "treatment" encompass the treatment of a disease state in a mammal, particularly in a human, and include: (a) preventing or delaying the occurrence of the disease state in a mammal, in particular, when such mammal is predisposed to the disease state but has not yet been diagnosed as having it; (b) inhibiting the disease state, i.e., arresting its development; and/or (c) achieving a full or partial reduction of the symptoms or disease state, and/or alleviating, ameliorating, lessening, or curing the disease or disorder and/or its symptoms.

[0098] In view of their activity as selective inhibitors IRAK-4, compounds of Formula (I) are useful in treating TLR/IL-1 family receptor associated diseases, but not limited to, inflammatory diseases such as Crohn's and ulcerative colitis, asthma, graft versus host disease, allograft rejection, chronic obstructive pulmonary disease; autoimmune diseases such as Graves' disease, rheumatoid arthritis, systemic lupus erythematosis, psoriasis; autoinflammatory diseases including CAPS, TRAPS, FMF, adult onset stills, systemic onset juvenile idiopathic arthritis, gout, gouty arthritis; metabolic diseases including type 2 diabetes, atherosclerosis, myocardial infarction; destructive bone disorders such as bone resorption disease, osteoarthritis, osteoporosis, multiple myeloma-related bone disorder; proliferative disorders such as acute myelogenous leukemia, chronic myelogenous leukemia; angiogenic disorders such as angiogenic disorders including solid tumors, ocular neovasculization, and infantile haemangiomas; infectious diseases such as sepsis, septic shock, and Shigellosis; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, cerebral ischemias or neurodegenerative disease caused by traumatic injury, oncologic and viral diseases such as metastatic melanoma, Kaposi's sarcoma, multiple myeloma, and HIV infection and CMV retinitis, AIDS, respectively.

[0099] More particularly, the specific conditions or diseases that may be treated with the inventive compounds include, without limitation, pancreatitis (acute or chronic), asthma, allergies, adult respiratory distress syndrome, chronic obstructive pulmonary disease, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosis, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, graft vs. host disease, inflammatory reaction induced by endotoxin, tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, gout, traumatic arthritis, rubella arthritis, acute synovitis, pancreatic β-cell disease; diseases characterized by massive neutrophil infiltration; rheumatoid spondylitis, gouty arthritis and other arthritic conditions, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoisosis, bone resorption disease, allograft rejections, fever and myalgias due to infection, cachexia secondary to infection, meloid formation, scar tissue formation, ulcerative colitis, pyresis, influenza, osteoporosis, osteoarthritis, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, sepsis, septic shock, and Shigellosis; Alzheimer's disease, Parkinson's disease, cerebral ischemias or neurodegenerative disease caused by traumatic injury; angiogenic disorders including solid tumors, ocular neovasculization, and infantile haemangiomas; viral diseases including acute hepatitis infection (including hepatitis A, hepatitis B and hepatitis C), HIV infection and CMV retinitis, AIDS, ARC or malignancy, and herpes; stroke, myocardial ischemia, ischemia in stroke heart attacks, organ hyposia, vascular hyperplasia, cardiac and renal reperfusion injury, thrombosis, cardiac hypertrophy, thrombin-induced platelet aggregation, endotoxemia and/or toxic shock syndrome, conditions associated with prostaglandin endoperoxidase syndase-2, and pemphigus vulgaris. Preferred methods of treatment are those wherein the condition is selected from Crohn's and ulcerative colitis, allograft rejection, rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis, and pemphigus vulgaris. Alternatively preferred methods of treatment are those wherein the condition is selected from ischemia reperfusion injury, including cerebral ischemia reperfusions injury arising from stroke and cardiac ischemia reperfusion injury arising from myocardial infarction. Another preferred method of treatment is one in which the condition is multiple myeloma.

[0100] In addition, the kinase inhibitors of the present invention inhibit the expression of inducible pro-inflammatory proteins such as prostaglandin endoperoxide synthase-2 (PGHS-2), also referred to as cyclooxygenase-2 (COX-2), IL-1, IL-6, IL-18, chemokines. Accordingly, additional IRAK-4-associated conditions include edema, analgesia, fever and pain, such as neuromuscular pain, headache, pain caused by cancer, dental pain and arthritis pain. The inventive compounds also may be used to treat veterinary viral infections, such as lentivirus infections, including, but not limited to equine infectious anemia virus; or retro virus infections, including feline immunodeficiency virus, bovine immunodeficiency virus, and canine immunodeficiency virus.

[0101] When the terms "IRAK-4-associated condition" or "IRAK-4 -associated disease or disorder" are used herein, each is intended to encompass all of the conditions identified above as if repeated at length, as well as any other condition that is affected by IRAK-4 kinase activity.

[0102] "Therapeutically effective amount" is intended to include an amount of a compound of the present invention that is effective when administered alone or in combination to inhibit IRAK-4 and/or treat diseases.

[0103] Accordingly, "therapeutically effective amount" is also intended to include an amount of the combination of compounds claimed that is effective to inhibit IRAK-4 and/or treat diseases associated with IRAK-4.

[0104] Exemplary of such other therapeutic (or "active") agents include corticosteroids, rolipram, calphostin, cytokine-suppressive anti-inflammatory drugs (CSAIDs), Interleukin-10, glucocorticoids, salicylates, nitric oxide, and other immunosuppressants; nuclear translocation inhibitors, such as deoxyspergualin (DSG); non-steroidal antiinflammatory drugs (NSAIDs) such as ibuprofen, celecoxib and rofecoxib; steroids such as prednisone or dexamethasone; antiviral agents such as abacavir; antiproliferative agents such as methotrexate, leflunomide, FK506 (tacrolimus, Prograf); cytotoxic drugs such as azathiprine and cyclophosphamide; TNF-α inhibitors such as tenidap, anti-TNF antibodies or soluble TNF receptor, and rapamycin (sirolimus or Rapamune) or derivatives thereof.

[0105] The above other therapeutic agents, when employed in combination with the compounds of the present invention, may be used, for example, in those amounts indicated in the Physicians' Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art. In the present invention, such other therapeutic agent(s) may be administered prior to, simultaneously with, or following the administration of the inventive compounds. The present invention also discloses pharmaceutical compositions capable of treating IRAK-4 kinase-associated conditions, including TLR and IL-1 family receptor mediated diseases as described above.

[0106] The inventive compositions may contain other therapeutic agents as described above and may be formulated, for example, by employing conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration (e.g., excipients, binders, preservatives, stabilizers, flavors, etc.) according to techniques such as those well known in the art of pharmaceutical formulation.

[0107] Accordingly, the present invention further includes compositions comprising one or more compounds of Formula (I) and a pharmaceutically acceptable carrier.

[0108] A "pharmaceutically acceptable carrier" refers to media generally accepted in the art for the delivery of biologically active agents to animals, in particular, mammals. Pharmaceutically acceptable carriers are formulated according to a number of factors well within the purview of those of ordinary skill in the art. These include without limitation the type and nature of the active agent being formulated; the subject to which the agent-containing composition is to be administered; the intended route of administration of the composition; and, the therapeutic indication being targeted. Pharmaceutically acceptable carriers include both aqueous and non-aqueous liquid media, as well as a variety of solid and semi-solid dosage forms. Such carriers can include a number of different ingredients and additives in addition to the active agent, such additional ingredients being included in the formulation for a variety of reasons, e.g., stabilization of the active agent, binders, etc., well known to those of ordinary skill in the art. Descriptions of suitable pharmaceutically acceptable carriers, and factors involved in their selection, are found in a variety of readily available sources such as, for example, Remington's Pharmaceutical Sciences, 17th ed., 1985.

[0109] The compounds of Formula (I) may be administered by any means suitable for the condition to be treated, which may depend on the need for site-specific treatment or quantity of drug to be delivered. Topical administration is generally preferred for skin-related diseases, and systematic treatment preferred for cancerous or pre-cancerous conditions, although other modes of delivery are contemplated. For example, the compounds may be delivered orally, such as in the form of tablets, capsules, granules, powders, or liquid formulations including syrups; topically, such as in the form of solutions, suspensions, gels or ointments; sublingually; bucally; parenterally, such as by subcutaneous, intravenous, intramuscular or intrasternal injection or infusion techniques (e.g., as sterile injectable aq. or non-aq. solutions or suspensions); nasally such as by inhalation spray; topically, such as in the form of a cream or ointment; rectally such as in the form of suppositories; or liposomally. Dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents may be administered. The compounds may be administered in a form suitable for immediate release or extended release. Immediate release or extended release may be achieved with suitable pharmaceutical compositions or, particularly in the case of extended release, with devices such as subcutaneous implants or osmotic pumps.

[0110] Exemplary compositions for topical administration include a topical carrier such as PLASTIBASE® (mineral oil gelled with polyethylene).

[0111] Exemplary compositions for oral administration include suspensions which may contain, for example, microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release tablets which may contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants such as those known in the art. The inventive compounds may also be orally delivered by sublingual and/or buccal administration, e.g., with molded, compressed, or freeze-dried tablets. Exemplary compositions may include fast-dissolving diluents such as mannitol, lactose, sucrose, and/or cyclodextrins. Also included in such formulations may be high molecular weight excipients such as celluloses (AVICEL®) or polyethylene glycols (PEG); an excipient to aid mucosal adhesion such as hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), sodium carboxymethyl cellulose (SCMC), and/or maleic anhydride copolymer (e.g., GANTREZ®); and agents to control release such as polyacrylic copolymer (e.g., CARBOPOL 934®). Lubricants, glidants, flavors, coloring agents and stabilizers may also be added for ease of fabrication and use.

[0112] Exemplary compositions for nasal aerosol or inhalation administration include solutions which may contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance absorption and/or bioavailability, and/or other solubilizing or dispersing agents such as those known in the art.

[0113] Exemplary compositions for parenteral administration include injectable solutions or suspensions which may contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.

[0114] Exemplary compositions for rectal administration include suppositories which may contain, for example, suitable non-irritating excipients, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures but liquefy and/or dissolve in the rectal cavity to release the drug.

[0115] The therapeutically-effective amount of a compound of the present invention may be determined by one of ordinary skill in the art, and includes exemplary dosage amounts for a mammal of from about 0.05 to 1000 mg/kg; 1-1000 mg/kg; 1-50 mg/kg; 5-250 mg/kg; 250-1000 mg/kg of body weight of active compound per day, which may be administered in a single dose or in the form of individual divided doses, such as from 1 to 4 times per day. It will be understood that the specific dose level and frequency of dosage for any particular subject may be varied and will depend upon a variety of factors, including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, drug combination, and severity of the particular condition. Preferred subjects for treatment include animals, most preferably mammalian species such as humans, and domestic animals such as dogs, cats, horses, and the like. Thus, when the term "patient" is used herein, this term is intended to include all subjects, most preferably mammalian species that are affected by mediation of IRAK-4 enzyme levels.

BIOLOGICAL ASSAYS


IRAK4 Inhibition Assay:



[0116] The assays were performed in U-bottom 384-well plates. The final assay volume was 30 µL prepared from 15 µL additions of enzyme and substrates (fluoresceinated peptide and ATP) and test compounds in assay buffer (20 mM HEPES pH 7.2, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT). The reaction was initiated by the combination of IRAK4 with substrates and test compounds. The reaction was incubated at room temperature for 60 min. and terminated by adding 45 uL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LabChip 3000 (Caliper, Hopkinton, MA) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assays are ATP, 500 µM; FL-IPTSPITTTYFFFKKK peptide 1.5 µM; IRAK4, 0.6 nM; and DMSO, 1.6%.
IRAK4 Inhibition Data
ExampleIRAK4 IC50 (µM)
1 0.0253

METHODS OF PREPARATION



[0117] The compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below.

[0118] The novel compounds of this invention may be prepared using the reactions and techniques described in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected. Also, in the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and work up procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents that are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods must then be used. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention. It will also be recognized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention. An authoritative account describing the many alternatives to the trained practitioner is Greene and Wuts (Protective Groups In Organic Synthesis, Third Edition, Wiley and Sons, 1999).

[0119] Triazole derivatives of general formula (I) can be prepared according to the method outlined in Scheme 1. Displacement of the C4 chloride of ethyl 4,6-dichloronicotinate (1) with an appropriately substituted amine can provide the C4 amino product (1.1) which can be further reacted with another amine in the presence of a catalyst, such as Pd, or under high temperatures to provide the bis-amino substituted pyridine (1.2). Hydrolysis of the ester with a suitable hydroxide source, such as KOH, can provide the carboxylic acid 1.3 which can be reacted with a suitable reagent, such as ethyl 2-amino-2-hydrazonoacetate, to afford the heterocycle precursor 1.4. Cyclization under thermal control can afford the general C5 triazole shown in Scheme 1.


EXAMPLES



[0120] Preparation of compounds of Formula (I), and intermediates used in the preparation of compounds of Formula (I), can be prepared using procedures shown in the following examples and related procedures. The methods and conditions used in these examples, and the actual compounds prepared in these examples, are not meant to be limiting, but are meant to demonstrate how the compounds of Formula (I) can be prepared. Starting materials and reagents used in these examples, when not prepared by a procedure described herein, are generally either commercially available, or are reported in the chemical literature, or may be prepared by using procedures described in the chemical literature.

[0121] In the examples given, the phrase "dried and concentrated" generally refers to drying of a solution in an organic solvent over either sodium sulfate or magnesium sulfate, followed by filtration and removal of the solvent from the filtrate (generally under reduced pressure and at a temperature suitable to the stability of the material being prepared). Column chromatography was performed with pre-packed silica gel cartridges using an Isco medium pressure chromatography apparatus (Teledyne Corporation), eluting with the solvent or solvent mixture indicated. Preparative high performance liquid chromatography (HPLC) was performed using a reverse phase column (Waters Sunfire C18, Waters Xbridge C18, Phenomenex Axia C18, YMC S5 ODS or the like) of a size appropriate to the quantity of material being separated, generally eluting with a gradient of increasing concentration of methanol or acetonitrile in water, also containing 0.05% or 0.1 % trifluoroacetic acid or 10 mM ammonium acetate, at a rate of elution suitable to the column size and separation to be achieved. Chemical names were determined using ChemDraw Ultra, version 9.0.5 (CambridgeSoft). The following abbreviations are used:

NaHCO3 (aq) - saturated aqueous sodium bicarbonate

brine - saturated aqueous sodium chloride

DCM - dichloromethane

DIEA - N,N-diisopropylethylamine

DMAP - 4-(N,N-dimethylamino)pyridine

DMF - N,N-dimethylformamide

DMSO - dimethyl sulfoxide

EDC - N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride

EtOAc - ethyl acetate

HOAT - 1-hydroxy-7-azabenzotriazole

HOBT - 1-hydroxybenzotriazole hydrate

rt - ambient room temperature (generally about 20-25 °C)

TEA - triethylamine

TFA - trifluoroacetic acid

THF - tetrahydrofuran


Triazoles



[0122] 



[0123] Synthesis of ethyl 6-chloro-4-(isopropylamino)nicotinate (2): A stirred solution of ethyl 4,6-dichloronicotinate (1) (10 g, 43.4 mmol), isopropyl amine (8 mL) and DIPEA (8 mL) in DMA (50 mL) were heated at 120 °C in a sealed tube for 3h. The reaction mixture was concentrated to dryness to remove excess of DMA from the reaction mass. The crude material obtained was purified by column chromatography through silica gel and EtOAC: pet. Ether as eluent to obtain the title compound (2). LC/MS: Acquity BEH C18 2.1 X 50mm, 1.8 micron; Solvent A = 0.1% TFA in water; Solvent B = 0.1% TFA in ACN; gradient 0-100% B over 2 min; retention time: 0.90min; LCMS (ES-API), m/z 243.7 (M+H).



[0124] Synthesis of 6-chloro-4-(isopropylamino)nicotinic acid (3): Ethyl 6-chloro-4-(cyclobutylamino)nicotinate (2) (3g, 12.3 mmol) in ethanol (20 mL) and water (10 mL) was stirred at rt. LiOH (61.7 mmol, 5 equiv.) was added and the reaction mixture was stirred at room temperature for 4h. The solvent was concentrated under reduced pressure. Diluted with EtOAc and added water. The aqueous layer was collected and acidified to pH 3-4 using solid citric acid. Solid material precipitated out. Filtered the solid material and dried under vacuum to furnish the title compound (3). 1H NMR: 400 MHz, DMSO-d6: δ 1.20 (d, J= 6.40 Hz, 6H), 3.80-3.88 (m, 1H), 6.80 (s, 1H), 8.20 (d, J= 7.60 Hz, 1H), 8.51 (s, 1H), 13.33 (bs, 1H).



[0125] Synthesis of ethyl 6-(benzo[d]thiazol-6-ylamino)-4-(isopropylamino)nicotinate (3): To a solution of ethyl 6-chloro-4-(isopropylamino)nicotinate (2) (5g, 20.66 mmol) in dioxane (30 mL): H2O (5 mL), 6-amino benzothiazole (20.66 mmol, 1 equiv.), xanthphos (8.2 mmol, 0.4 equiv.) and Na2CO3 (82.6 mmol, 4 equiv.) were added and degassed for 10 min. To the reaction mixture Pd2(dba)3 (8.2 mmol, 0.4 equiv.) was added and degassed again for 10 min. It was then heated at 115°C, overnight. The reaction was cooled and filtered through small pad of celite. The filtrate obtained was concentrated to provide crude material. The crude material was purified by column chromatography through silica gel and EtOAC: pet. Ether as eluent to afford ethyl 6-(benzo[d]thiazol-6-ylamino)-4-(isopropylamino)nicotinate (3). LC/MS: Acquity BEH C18 2.1 X 50mm, 1.8 micron; Solvent A = 0.1 % TFA in water; Solvent B = 0.1 % TFA in ACN; gradient 0-100% B over 2 min; retention time: 0.78 min; LCMS (ES-API), m/z 357.8 (M+H).



[0126] Synthesis of 6-(benzo[d]thiazol-6-ylamino)-4-(isopropylamino)nicotinic acid (4): Ethyl 6-(benzo[d]thiazol-6-ylamino)-4-(isopropylamino)nicotinate (3) (1g, 2.8 mmol) in ethanol (20 mL) and water (5 mL) was stirred at rt then added LiOH (14 mmol, 5 equiv.). The reaction mixture was stirred at room temperature for 4h, the then heated at 70 °C for 1h. The solvent was concentrated under reduced pressure, diluted with EtOAc and added water. The aqueous layer was collected and acidified to pH 3-4 using solid citric acid. Solid material precipitated out. Filtered the solid material and dried under vacuum to furnish the title compound (4). LC/MS: Acquity BEH C18 2.1 X 50mm, 1.8 micron; Solvent A = 0.1 % TFA in water; Solvent B = 0.1 % TFA in ACN; gradient 0-100% B over 2 min; retention time: 0.65 min; LCMS (ES-API), m/z 329.8 (M+H).



[0127] Synthesis of ethyl 2-amino-2-hydrazonoacetate (6): Ethyl 2-amino-2-thioxoacetate (5) (5g, 37.5 mmol) was dissolved in ethanol and cooled to 0 °C. Hydrazine in THF (1M, 37.5 mmol) was added dropwise and stirred at ambient temperature for 1h. The reaction mixture was concentrated, white flakes of ethyl 2-amino-2-hydrazonoacetate were obtained.



[0128] Synthesis of ethyl 2-amino-2-(2-(6-(benzo[d]thiazol-6-ylamino)-4-(isopropylamino)nicotinoyl)hydrazono)acetate (7): To a stirred solution of 6-(benzo[d]thiazol-6-ylamino)-4-(isopropylamino)nicotinic acid (4) (500 mg, 3.8 mmol) and ethyl 2-amino-2-hydrazonoacetate (6) (3.8 mmol, 1 equiv.) in DMF (10 mL), HATU (7.63 mmol, 2 equiv.) and DIPEA (15.2 mmol, 4 equiv.) were added and stirred for 4h. The reaction mixture was concentrated under reduced pressure to remove excess of DMF. The residue obtained was partitioned between water and EtOAc. The organic layer was separated, dried over Na2SO4, filtered and concentrated. The crude material obtained was purified by column chromatography through silica gel and MeOH: CHCl3 as eluent to afford the title compound.

Example 1



[0129] 



[0130] Ethyl 2-amino-2-(2-(6-(benzo[d]thiazol-6-ylamino)-4-(isopropylamino)nicotinoyl)hydrazono)acetate (7) (300 mg, 0.679 mmol) was taken in a sealed tube and heated at 180 °C for 1h. The reaction mass was dissolved in methanol then concentrated. The crude material obtained was purified by flash column chromatography through silica gel and MeOH: CHCl3 as eluting agents. The material was further purified by prep HPLC to obtain N2-(benzo[d]thiazol-6-yl)-N4-isopropyl-5-(4H-1,2,4-triazol-3-yl)pyridine-2,4-diamine. 1H NMR: 400 MHz, CD3OD: δ 1.32 (d, J= 4.00 Hz, 6H), 1.43 (t, J= 6.80 Hz, 3H), 3.72-3.74 (m, 1H), 4.41 (q,J= 6.80 Hz, 2H), 6.17 (s, 1H), 7.48 (dd, J= 2.40, 8.8 Hz, 1H), 7.93 (d, J= 8.80 Hz, 1H), 8.33 (s, 1H), 8.61 (s, 1H), 9.02 (s, 1H). LC/MS: Ascentis Express C18, 5 × 2.1 mm- 2.7 µm; Solvent A = 2% ACN: 98% H2O: 10 mM NH4COOH; Solvent B = 98% ACN: 2% H2O: 10 mM NH4COOH; gradient 0-100% B over 3 min; retention time: 1.789 min; LCMS (ES-API), m/z 422.0 (M-H). HPLC: XBridge (150 × 4.6 mm), 3.5 micron; Solvent A = 5% ACN: 95% H2O: 0.05% TFA pH= 2.5; Solvent B = 95% ACN: 5% H2O: 0.05% TFA pH= 2.5; gradient 0-100% B over 15 min (23 min run time); Flow rate: 1.0 µL/min; Retention time: 7.569 min; Purity: 99%.

Example 174


(2S,3S)-3-((2-(Benzo[d]thiazol-6-ylamino)-5-(1H-1,2,4-triazol-5-yl)pyridin-4-yl)amino)-3-phenylpropane-1,2-diol



[0131] 





[0132] Step 1: A mixture of 4,6-dichloronicotinonitrile (760 mg, 4.39 mmol), (2S,3S)-3-amino-3-phenylpropane-1,2-diol (780 mg, 4.66 mmol) (Pico, Anna; Moyano, Albert ARKIVOC (Gainesville, FL, United States) (2007), (4), 132-156) and DIPEA (921 µL, 5.27 mmol) in DMA (4393 µL) was stirred at 50 °C for 2.5 hours after which LCMS indicated ∼98% reaction completion. The vessel was cooled to room temperature and the dark solution was partitioned between ethyl acetate and water. The organic portion was washed with water and the combined aqueous layers were extracted with ethyl acetate. The organics were combined, dried over anhyrdous sodium sulfate, filtered and concentrated. The mixture was dissolved in 2 mL of DCM and purified on a 40G ISCO column using 5-100% EA/Heptane. Following concentration, the regioisomers were collected as isolates 01 and 02.



[0133] Step 2: A mixture of 6-chloro-4-((1S,2S)-2,3-dihydroxy-1-phenylpropylamino)nicotinonitrile (0.108 g, 0.356 mmol), benzo[d]thiazol-6-amine (0.187 g, 1.244 mmol) and NMP (1.422 mL) was stirred at 150 °C for 1 hour in a microwave reactor. The vessel was cooled to room temperature, diluted with water and filtered. Following drying on a buchner funnel, 6-(benzo[d]thiazol-6-ylamino)-4-((1S,2S)-2,3-dihydroxy-1-phenylpropylamino)nicotinonitrile (0.122 g, 0.292 mmol, 82 % yield) was collected as a yellowish solid. LC-MS (m/z, M+1= 418), Waters sunfire 4.6x50mm C18 5um 4 min/1 min hold time 0-100% (A-B) A=10% MeOH-90% water-0.1 %TFA, B=90% MeOH-10% water - 0.1 %TFA RT= 2.06.



[0134] Step 3: In a tall reaction tube was added 6-(benzo[d]thiazol-6-ylamino)-4-((1S,2S)-2,3-dihydroxy-1-phenylpropylamino)nicotinonitrile (0.075 g, 0.180 mmol), THF (0.898 mL) and hydrazine (1.692 mL, 53.9 mmol). The reaction was heated to 95 °C for 16 hrs. The reaction was cooled and concentrated. MeOH (0.898 mL), formaldehyde (0.025 mL, 0.898 mmol) and trimethyl orthoformate (0.099 mL, 0.898 mmol) were added and the reaction stirred at rt overnight. The mixture was concentrated, dilute with DMF and filtered. Purification was done by HPLC using 40-100% MeOH/Water/TFA over 10 minutes. Following concentration, collected (2S,3S)-3-(2-(benzo[d]thiazol-6-ylamino)-5-(1H-1,2,4-triazol-5-yl)pyridin-4-ylamino)-3-phenylpropane-1,2-diol, TFA (0.004 g, 6.63 µmol, 3.69 % yield) as a white solid. LC-MS (m/z, M+1= 460), Waters sunfire 4.6x50mm C18 5um 4 min/1 min hold time 0-100% (A-B) A=10% MeOH-90% water-0.1%TFA, B=90% MeOH-10% water - 0.1%TFA RT= 2.2. 1H NMR (400MHz, METHANOL-D3) d 9.32 (s, 1H), 8.64 (s, 1H), 8.44 (s, 1H), 8.09 (d, J=8.8 Hz, 1H), 7.84 (d, J=2.2 Hz, 1H), 7.39 - 7.22 (m,7H), 5.98 (s, 1H), 4.75 (d, J=4.0 Hz, 1H), 4.11 - 4.04 (m, 1H), 3.50 - 3.42 (m, 1H), 3.41 - 3.34 (m, 1H).


Claims

1. A compound according to formula (I):

or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein

A is a triazole optionally substituted by 0-2 R;

R is hydrogen, R1, halogen, cyano, nitro, -OR1, -C(=O)-R1, -C(=O)O- R1, -C(=O)NR11-R1, -S(=O)2-R1, -NR11C(=O)- R1, -NR11C(=O)NR11R1, -NR11C(=O)O- R1, -NR11S(=O)2R1 or -NR11R1 or selected from the following groups:

























R1 is C1-6 alkyl substituted with 0-4 R1a, C1-6 haloalkyl, C2-6 alkenyl substituted with 0-3 R1a, C2-6 alkynyl substituted with 0-3 R1a, C3-10 cycloalkyl substituted with 0-3 R1a, C6-10 aryl substituted with 0-3 R1a, a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R1a, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R1a;

R1a is hydrogen, =O, F, Cl, Br, OCF3, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyl substituted with 0-2 Ra, C1-6 haloalkyl, -(CH2)r-3-14 membered carbocycle substituted with 0-3 Ra, or -(CH2)r-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-3 Ra;

R2 is C6-10 aryl substituted with 0-4 R2a, a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, substituted with 1-4 R2a, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-4 R2a;

R2a at each occurrence is independently selected from hydrogen, =O, halo, OCF3, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyl substituted with 0-2 Ra, C1-6 haloalkyl, -(CH2)r-3-14 membered carbocycle substituted with 0-1 Ra, or -(CH2)r-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-2 Ra;

R3 is C1-6 alkyl substituted with 0-3 R3a, C1-6 haloalkyl, C2-6 alkenyl substituted with 0-3 R3a, C2-6 alkynyl substituted with 0-3 R3a, C3-10 cycloalkyl substituted with 0-3 R3a, C6-10 aryl substituted with 0-3 R3a, a 5-10 membered heterocyclyl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R3a or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R3a;

R3a is hydrogen, =O, F, Cl, Br, OCF3, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyl substituted with 0-2 Ra, C1-6haloalkyl, -(CH2)r-3-14 membered carbocycle substituted with 0-1 Ra, or -(CH2)r-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-1 Ra;

R4 and R5 are independently selected from hydrogen, C1-4 alkyl substituted with 0-1 Rf, (CH2)-phenyl substituted with 0-3 Rd, and a -(CH2)-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p,;

R6 is selected from hydrogen, =O, F, Cl, Br, OCF3, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyl substituted with 0-2 Ra, C1-6haloalkyl, -(CH2)r-3-14 membered carbocycle substituted with 0-3 Ra, or -(CH2)r-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-3 Ra;

R11 at each occurrence is independently hydrogen, Re, C1-4 alkyl substituted with 0-1 Rf, CH2-phenyl substituted with 0-3 Rd, or -(CH2)-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-3 Rd; or

R11 and along with another R11, or R1 on the same nitrogen atom may join to form an heterocycle;

Ra is hydrogen, F, Cl, Br, OCF3, CF3, CHF2, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyl substituted with 0-1 Rf, C1-6 haloalkyl, -(CH2)r-3-14 membered carbocycle, or -(CH2)r-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p; or two Ra on adjacent or the same carbon atom form a cyclic acetal of the formula -O-(CH2)n-O-, or -O-CF2-O-, wherein n is selected from 1 or 2;

Rb is hydrogen, Re, C1-6 alkyl substituted with 0-2 Rd, C1-6 haloalkyl, C3-6 cycloalkyl substituted with 0-2 Rd, or (CH2)r-phenyl substituted with 0-3 Rd;

Rc is C1-6 alkyl substituted with 0-1 Rf, C3-6 cycloalkyl, or (CH2)r-phenyl substituted with 0-3 Rf;

Rd is hydrogen, F, Cl, Br, OCF3, CF3, CN, NO2, -ORe, -(CH2)rC(O)Rc, -NReRe, -NReC(O)ORc, C1-6 alkyl, or (CH2)r-phenyl substituted with 0-3 Rf;

Re is selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r-phenyl substituted with 0-3 Rf;

Rf is hydrogen, halo, NH2, OH, or O(C1-6alkyl);

p is 0, 1, or 2;

r is 0, 1,2, 3, or 4; and

m is 0, 1, or 2.


 
2. A compound of claim 1, or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein A is

and X1 and X2 are independently selected from N or C-R, provided that one of X1 and X2 is selected from N and the other from C-R.
 
3. A compound of any one of claims 1-2, or a pharmaceutically-acceptable salt thereof, wherein R2 is phenyl, pyridyl, pyrimidinyl, naphthyl, indolinyl, benzothiazolyl, pyrazolopyridinyl, benzoisothiazolyl, triazolopyridinyl, imidazopyridinyl, benzooxazolyl, triazolopyridinyl, imidazopyridinyl, pyridopyrazinyl, quinazolinyl, pyridopyrazinyl, benzooxadiazolyl, benzothiadiazolyl, benzoimidazolyl, triazolopyridinyl, imdazopyridazinyl, pyridopyrazinyl, naphthyridinyl, quinoxalinyl, phthalazinyl, quinolinyl, indolyl, benzothiazolyl, benzodioxolyl, benzothienyl, isoquinolinyl, benzopyranyl, indolizinyl, benzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, pyrrolopyridyl, furopyridyl, isoindolyl, or quinazolinyl, each group substituted by 1-4 groups selected from R2a.
 
4. A compound of any one of claims 1-3, or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein m is 0.
 
5. A compound of any one of claims 1-4, or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein both R4 and R5 are hydrogen.
 
6. A compound of any one of claims 1-5 having the following formula

or a stereoisomer or pharmaceutically salt thereof, wherein:

X1 and X2 are independently selected from N or C-R, provided one of X1 and X2 is selected from N and the other from C-R;

R is hydrogen, R1, halogen,-C(=O)-R1, -C(=O)OR1, -C(=O)NR11R1 or -NR11R1;

R1 is C1-6 alkyl substituted with 0-4 R1a, C1-6 haloalkyl, C2-6 alkenyl substituted with 0-3 R1a, C2-6 alkynyl substituted with 0-3 R1a, C3-10 cycloalkyl substituted with 0-3 R1a, C6-10 aryl substituted with 0-3 R1a, a 5-10 membered heterocycle containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R1a, or a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R1a;

R1a is hydrogen, =O, F, Cl, Br, OCF3, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6alkyl substituted with 0-2 Ra, C1-6haloalkyl, -(CH2)r-3-14 membered carbocycle substituted with 0-1 Ra, or -(CH2)r-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-1 Ra;

R2 is phenyl, pyridyl, pyrimidinyl, naphthyl, indolinyl, benzothiazolyl, pyrazolopyridinyl, benzoisothiazolyl, triazolopyridinyl, imidazopyridinyl, benzooxazolyl, triazolopyridinyl, imidazopyridinyl, pyridopyrazinyl, quinazolinyl, pyridopyrazinyl, benzooxadiazolyl, benzothiadiazolyl, benzoimidazolyl, triazolopyridinyl, imdazopyridazinyl, pyridopyrazinyl, naphthyridinyl, quinoxalinyl, phthalazinyl, quinolinyl, indolyl, benzothiazolyl, benzodioxolyl, benzothienyl, isoquinolinyl, benzopyranyl, indolizinyl, benzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, pyrrolopyridyl, furopyridyl, isoindolyl, or quinazolinyl each group substituted by 1-4 groups selected from R2a;

R2a is hydrogen, =O, F, Cl, Br, OCF3, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyl substituted with 0-2 Ra, C1-6haloalkyl, -(CH2)r-3-14 membered carbocycle substituted with 0-1 Ra, or -(CH2)r-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-1 Ra;

R3 is C1-6 alkyl substituted with 0-3 R3a; or a C3-7cycloalkyl, phenyl, tetrahydropyranyl, tetrahydrofuranyl, or oxetane ring, each ring optionally substituted with 0-3 R3a;

R3a is hydrogen, =O, F, Cl, Br, OCF3, CF3, CHF2, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyl substituted with 0-2 Ra, C1-6 haloalkyl, -(CH2)r-3-14 membered carbocycle substituted with 0-1 Ra, or -(CH2)r-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-1 Ra;

R11 at each occurrence is independently hydrogen, C1-4 alkyl substituted with 0-1 Rf, CH2-phenyl substituted with 0-3 Rd, or -(CH2)-5-7 membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p substituted with 0-3 Rd;

Ra is hydrogen, Cl, Br, OCF3, CF3, CHF2, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyl, C1-6 haloalkyl, -(CH2)r-3-14 membered carbocycle, or -(CH2)r-5-7 membered heterocycle or heteroaryl, each comprising carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)p, alternatively two Ra on adjacent or the same carbon atom form a cyclic acetal of the formula -O-(CH2)n-O-, or -O-CF2-O-, wherein n is selected from 1 or 2;

Rb is hydrogen, C1-6 alkyl substituted with 0-2 Rd, C1-6 haloalkyl, C3-6 cycloalkyl substituted with 0-2 Rd, or (CH2)r-phenyl substituted with 0-3 Rd;

Rc is C1-6 alkyl, C3-6 cycloalkyl, or (CH2)r-phenyl substituted with 0-3 Rf;

Rd is hydrogen, F, Cl, Br, OCF3, CF3, CN, NO2, -ORe, -(CH2)rC(O)Rc, -NReRe, -NReC(O)ORc, C1-6 alkyl, or (CH2)r-phenyl substituted with 0-3 Rf;

Re is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, or (CH2)r-phenyl substituted with 0-3 Rf;

Rf is hydrogen, halo, NH2, OH, or O(C1-6alkyl);

r is 0, 1,2, 3, or 4; and

p is 0, 1, or 2.


 
7. A compound of any one of claims 1-2 or 4-6, or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein R2 is selected from













each group substituted by 0-4 R2a.
 
8. A compound of any one of claims 1-7, or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein R2 is selected from

each group optionally substituted by 0-3 R2a.
 
9. A compound of any one of claims 1-7, or a stereoisomer or pharmaceutically-acceptable salt thereof wherein R2 is selected

or

each group optionally substituted by 0-3 R2a.
 
10. A compound of any one of claims 1-7, or a stereoisomer or pharmaceutically-acceptable salt thereof wherein R2 is

and Y is Cl, F, Br, CN, -OC1-6alkyl, C1-6alkyl, -haloC1-6alkyl, or NH2.
 
11. A compound of any one of claims 1-8, or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein R is selected from the following groups:
























 
12. A compound of any one of claims 1-11, or a stereoisomer or pharmaceutically-acceptable salt thereof wherein X2 is N and X1 is CR; and R is hydrogen or. C1-6alkyl.
 
13. A compound of any one of claims 1-12, or a stereoisomer or pharmaceutically-acceptable salt thereof wherein R3 is C1-6alkyl substituted with 0-3 R3a or phenyl optionally substituted with 0-3 R3a.
 
14. A compound of any one of claims 1-13 wherein the compounds is


 
15. A pharmaceutical composition comprising a compound of any one of claims 1-14 and a pharmaceutically acceptable carrier or diluent.
 
16. Acompound of any one of claims 1-14 for use as a medicament.
 
17. A compound of any one of claims 1-14 for use in the treatment of an inflammatory or autoimmune disease.
 


Ansprüche

1. Verbindung gemäß Formel (I):

oder ein Stereoisomer oder ein pharmazeutisch akzeptables Salz davon, wobei

A ein Triazol ist, das optional substituiert ist durch 0-2 R;

R Folgendes ist: Wasserstoff, R1, Halogen, Cyano, Nitro, -OR1, -C(=O)-R1, - C(=O)O- R1, -C(=O)NR11-R1, -S(=O)2-R1, -NR11C(=O)- R1, -NR11C(=O)NR11R1, - NR11C(=O)O- R1, -NR11S(=O)2R1 oder -NR11R1 oder aus folgenden Gruppen ausgewählt wird:

























R1 Folgendes ist: C1-6-Alkyl, das mit 0-4 R1a substituiert ist, C1-6-Haloalkyl, C2-6-Alkenyl, das mit 0-3 R1a substituiert ist, C2-6-Alkynyl, das mit 0-3 R1a substituiert ist, C3-10-Cycloalkyl, das mit 0-3 R1a substituiert ist, C6-10-Aryl, das mit 0-3 R1a substituiert ist, ein 5-10-gliedriger Heterocyclus, der 1-4 Heteroatome enthält, die aus N, O, und S ausgewählt sind, der mit 0-3 R1a substituiert ist, oder ein 5-10-gliedriges Heteroaryl, das 1-4 Heteroatome enthält, die aus N, O, und S ausgewählt sind, das mit 0-3 R1a substituiert ist.

R1a Folgendes ist: Wasserstoff, =O, F, Cl, Br, OCF3, CN, NO2, -(CH2)rORb,-(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, - (CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, - S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6-Alkyl, das mit 0-2 Ra substituiert ist, C1-6-Haloalkyl, -(CH2)r-3-14-gliedriger Kohlenstoffcyclus, der mit 0-3 Ra substituiert ist, oder -(CH2)r-5-7-gliedriger Heterocyclus oder Heteroaryl, die jeweils Kohlenstoffatome und 1-4 Heteroatome umfassen, die aus N, O, und S(O)p ausgewählt sind, die mit 0-3 Ra substituiert sind;

R2 Folgendes ist: C6-10-Aryl, das mit 0-4 R2a substituiert ist, ein 5-10-gliedriger Heterocyclus, der 1-4 Heteroatome enthält, die aus N, O, und S ausgewählt sind, das mit 1-4 R2a substituiert ist, oder ein 5-10-gliedriges Heteroaryl, das 1-4 Heteroatome enthält, die aus N, O, und S ausgewählt sind, das mit 0-4 R2a substituiert ist.

R2a bei jedem Vorkommen unabhängig aus Folgendem ausgewählt wird: Wasserstoff, =O, Halogen, OCF3, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb,-(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, - (CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, - NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6-Alkyl, das mit 0-2 Ra substituiert ist, C1-6-Haloalkyl, -(CH2)r-3-14-gliedriger Kohlenstoffcyclus, der mit 0-1 Ra substituiert ist, oder -(CH2)r-5-7-gliedriger Heterocyclus oder Heteroaryl, die jeweils Kohlenstoffatome und 1-4 Heteroatome umfassen, die aus N, O, und S(O)p ausgewählt sind, die mit 0-2 Ra substituiert sind;

R3 Folgendes ist: C1-6-Alkyl, das mit 0-3 R3a substituiert ist, C1-6-Haloalkyl, C2-6-Alkenyl, das mit 0-3 R3a substituiert ist, C2-6-Alkynyl, das mit 0-3 R3a substituiert ist, C3-10-Cycloalkyl, das mit 0-3 R3a substituiert ist, C6-10-Aryl, das mit 0-3 R3a substituiert ist, ein 5-10-gliedriges Heterocyclyl, das 1-4 Heteroatome enthält, die aus N, O, und S, ausgewählt sind, das mit 0-3 R3a substituiert ist, oder ein 5-10-gliedriges Heteroaryl, das 1-4 Heteroatome enthält, die aus N, O, und S, ausgewählt sind, das mit 0-3 R3a substituiert ist;

R3a Folgendes ist: Wasserstoff, =O, F, Cl, Br, OCF3, CN, NO2, -(CH2)rORb,-(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, - (CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, - S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6-Alkyl, das mit 0-2 Ra substituiert ist, C1-6-Haloalkyl, -(CH2)r-3-14-gliedriger Kohlenstoffcyclus, der mit 0-1 Ra substituiert ist, oder -(CH2)r-5-7-gliedriger Heterocyclus oder Heteroaryl, die jeweils Kohlenstoffatome und 1-4 Heteroatome umfassen, die aus N, O, und S(O)p ausgewählt sind, die mit 0-1 Ra substituiert sind;

R4 und R5 unabhängig aus Folgendem ausgewählt sind: Wasserstoff, C1-4-Alkyl, das mit 0-1 Rf substituiert ist, (CH2)-Phenyl, das mit 0-3 Rd substituiert ist, und ein -(CH2)-5-7-gliedriger Heterocyclus, der Kohlenstoffatome und 1-4 Heteroatome umfasst, die aus N, O, und S(O)P ausgewählt sind;

R6 aus Folgendem ausgewählt ist: Wasserstoff, =O, F, Cl, Br, OCF3, CN, NO2, - (CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb,-(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)NRbC(O)Rc, -(CH2)rNRbC(O)ORc, - NRbC(O)NR11R11, -S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6-Alkyl, das mit 0-2 Ra substituiert ist, C1-6-Haloalkyl, -(CH2)r-3-14-gliedrigem Kohlenstoffcyclus, der mit 0-3 Ra substituiert ist, oder -(CH2)r-5-7-gliedrigem Heterocyclus oder Heteroaryl, die jeweils Kohlenstoffatome und 1-4 Heteroatome umfassen, die aus N, O, und S(O)p ausgewählt sind, die mit 0-3 Ra substituiert sind;

R11 bei jedem Vorkommen unabhängig Folgendes ist: Wasserstoff, Re, C1-4-Alkyl, das mit 0-1 Rf substituiert ist, CH2-Phenyl, das mit 0-3 Rd substituiert ist, oder -(CH2)-5-7-gliedriger Heterocyclus, der Kohlenstoffatome und 1-4 Heteroatome umfasst, die aus N, O, und S(O)p ausgewählt sind, die mit 0-3 Rd substituiert sind; oder

R11 zusammen mit einem anderen R11 oder R1 auf demselben Stickstoffatom sich verbinden können, um einen Heterocyclus zu bilden;

Ra Folgendes ist: Wasserstoff, F, Cl, Br, OCF3, CF3, CHF2, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, - (CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11,-S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6-Alkyl, das mit 0-1 Rf substituiert ist, C1-6-Haloalkyl, -(CH2)r-3-14-gliedriger Kohlenstoffcyclus oder -(CH2)r-5-7-gliedriger Heterocyclus oder Heteroaryl, die jeweils Kohlenstoffatome und 1-4 Heteroatome umfassen, die aus N, O, und S(O)p ausgewählt sind; oder wobei zwei Ra an benachbarten oder demselben Kohlenstoffatom ein cyclisches Acetal der Formel -O-(CH2)n-O- oder -O-CF2-O- bilden, wobei n aus 1 oder 2 ausgewählt wird;

Rb Folgendes ist: Wasserstoff, Re, C1-6-Alkyl, das mit 0-2 Rd substituiert ist, C1-6-Haloalkyl, C3-6-Cycloalkyl, das mit 0-2 Rd substituiert ist, oder (CH2)r-Phenyl, das mit 0-3 Rd substituiert ist;

Rc Folgendes ist: C1-6-Alkyl, das mit 0-1 Rf substituiert ist, C3-6-Cycloalkyl oder (CH2)r-Phenyl, das mit 0-3 Rf substituiert ist;

Rd Folgendes ist: Wasserstoff, F, Cl, Br, OCF3, CF3, CN, NO2, -ORe,-(CH2),C(O)Rc, -NReRe, -NReC(O)ORc, C1-6-Alkyl oder (CH2)r-Phenyl, das mit 0-3 Rf substituiert ist;

Re aus Wasserstoff, C1-6-Alkyl, C3-6-Cycloalkyl und (CH2)r-Phenyl, das mit 0-3 Rf substituiert ist, ausgewählt wird;

Rf Wasserstoff, Halogen, NH2, OH oder O(C1-6-Alkyl) ist;

p 0, 1 oder 2 ist;

r 0, 1, 2, 3 oder 4 ist; und

m 0, 1 oder 2 ist.


 
2. Verbindung nach Anspruch 1 oder ein Stereoisomer oder pharmazeutisch akzeptables Salz davon, wobei A

ist und X1 und X2 unabhängig aus N oder C-R ausgewählt sind, vorausgesetzt, dass eines von X1 und X2 aus N und das andere aus C-R ausgewählt ist.
 
3. Verbindung nach einem der Ansprüche 1-2 oder ein pharmazeutisch akzeptables Salz davon, wobei R2 Folgendes ist: Phenyl, Pyridyl, Pyrimidinyl, Naphthyl, Indolinyl, Benzothiazolyl, Pyrazolopyridinyl, Benzoisothiazolyl, Triazolopyridinyl, Imidazopyridinyl, Benzooxazolyl, Triazolopyridinyl, Imidazopyridinyl, Pyridopyrazinyl, Quinazolinyl, Pyridopyrazinyl, Benzooxadiazolyl, Benzothiadiazolyl, Benzoimidazolyl, Triazolopyridinyl, Imdazopyridazinyl, Pyridopyrazinyl, Naphthyridinyl, Quinoxalinyl, Phthalazinyl, Quinolinyl, Indolyl, Benzothiazolyl, Benzodioxolyl, Benzothienyl, Isoquinolinyl, Benzopyranyl, Indolizinyl, Benzofuranyl, Chromonyl, Coumarinyl, Benzopyranyl, Cinnolinyl, Pyrrolopyridyl, Furopyridyl, Isoindolyl oder Quinazolinyl, wobei jede Gruppe durch 1-4 Gruppen substituiert wird, die aus R2a ausgewählt sind.
 
4. Verbindung nach einem der Ansprüche 1-3 oder ein Stereoisomer oder ein pharmazeutisch akzeptables Salz davon, wobei m 0 ist.
 
5. Verbindung nach einem der Ansprüche 1-4 oder ein Stereoisomer oder ein pharmazeutisch akzeptables Salz davon, wobei sowohl R4 als auch R5 Wasserstoff sind.
 
6. Verbindung nach einem der Ansprüche 1-5, die folgende Formel aufweist:

oder ein Stereoisomer oder pharmazeutisch akzeptables Salz davon, wobei:

X1 und X2 unabhängig aus N oder C-R ausgewählt sind, vorausgesetzt, dass eines von X1 und X2 aus N und das andere aus C-R ausgewählt ist;

R Folgendes ist: Wasserstoff, R1, Halogen, -C(=O)-R1, -C(=O)OR1, -C(=O)NR11R1 oder -NR11R1;

R1 Folgendes ist: C1-6-Alkyl, das mit 0-4 R1a substituiert ist, C1-6-Haloalkyl, C2-6-Alkenyl, das mit 0-3 R1a substituiert ist, C2-6-Alkynyl, das mit 0-3 R1a substituiert ist, C3-10-Cycloalkyl, das mit 0-3 R1a substituiert ist, C6-10-Aryl, das mit 0-3 R1a substituiert ist, ein 5-10-gliedriger Heterocyclus, der 1-4 Heteroatome enthält, die aus N, O, und S, ausgewählt sind, der mit 0-3 R1a substituiert ist, oder ein 5-10-gliedriges Heteroaryl, das 1-4 Heteroatome enthält, die aus N, O, und S, ausgewählt sind, das mit 0-3 R1a substituiert ist;

R1a Folgendes ist: Wasserstoff, =O, F, Cl, Br, OCF3, CN, NO2, -(CH2)rORb,-(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, - (CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11,-S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6-Alkyl, das mit 0-2 Ra substituiert ist, C1-6-Haloalkyl, -(CH2)r-3-14-gliedriger Kohlenstoffcyclus, der mit 0-1 Ra substituiert ist, oder -(CH2)r-5-7-gliedriger Heterocyclus, der Kohlenstoffatome und 1-4 Heteroatome umfasst, die aus N, O, und S(O)P ausgewählt sind, der mit 0-1 Ra substituiert ist;

R2 Folgendes ist: Phenyl, Pyridyl, Pyrimidinyl, Naphthyl, Indolinyl, Benzothiazolyl, Pyrazolopyridinyl, Benzoisothiazolyl, Triazolopyridinyl, Imidazopyridinyl, Benzooxazolyl, Triazolopyridinyl, Imidazopyridinyl, Pyridopyrazinyl, Quinazolinyl, Pyridopyrazinyl, Benzooxadiazolyl, Benzothiadiazolyl, Benzoimidazolyl, Triazolopyridinyl, Imdazopyridazinyl, Pyridopyrazinyl, Naphthyridinyl, Quinoxalinyl, Phthalazinyl, Quinolinyl, Indolyl, Benzothiazolyl, Benzodioxolyl, Benzothienyl, Isoquinolinyl, Benzopyranyl, Indolizinyl, Benzofuranyl, Chromonyl, Coumarinyl, Benzopyranyl, Cinnolinyl, Pyrrolopyridyl, Furopyridyl, Isoindolyl oder Quinazolinyl wobei jede Gruppe durch 1-4 Gruppen substituiert wird, die aus R2a ausgewählt werden;

R2a Folgendes ist: Wasserstoff, =O, F, Cl, Br, OCF3, CN, NO2, -(CH2)rORb,-(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, - (CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11,-S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6-Alkyl, das mit 0-2 Ra substituiert ist, C1-6-Haloalkyl, -(CH2)r-3-14-gliedriger Kohlenstoffcyclus, der mit 0-1 Ra substituiert ist, oder -(CH2)R-5-7-gliedriger Heterocyclus, der Kohlenstoffatome und 1-4 Heteroatome umfasst, die aus N, O, und S(O)p ausgewählt sind, die mit 0-1 Ra substituiert sind;

R3 Folgendes ist: C1-6-Alkyl, das mit 0-3 R3a substituiert ist; oder ein C3-7-Cycloalkyl-, Phenyl-, Tetrahydropyranyl-, Tetrahydrofuranyl- oder Oxetanring, wobei jeder Ring optional mit 0-3 R3a substituiert ist;

R3a Folgendes ist: Wasserstoff, =O, F, Cl, Br, OCF3, CF3, CHF2, CN, NO2, - (CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, - (CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, - NRbC(O)NR11R11, -S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6-Alkyl, das mit 0-2 Ra substituiert ist, C1-6-Haloalkyl, -(CH2)r-3-14-gliedriger Kohlenstoffcyclus, der mit 0-1 Ra substituiert ist, oder -(CH2)r-5-7-gliedriger Heterocyclus, der Kohlenstoffatome und 1-4 Heteroatome umfasst, die aus N, O, und S(O)p ausgewählt sind, die mit 0-1 Ra substituiert sind;

R11 bei jedem Vorkommen unabhängig Folgendes ist: Wasserstoff, C1-4-Alkyl, das mit 0-1 Rf substituiert ist, CH2-Phenyl, das mit 0-3 Rd substituiert ist, oder -(CH2)-5-7-gliedriger Heterocyclus, der Kohlenstoffatome und 1-4 Heteroatome umfasst, die aus N, O, und S(O)p ausgewählt sind, die mit 0-3 Rd substituiert sind;

Ra Folgendes ist: Wasserstoff, Cl, Br, OCF3, CF3, CHF2, CN, NO2, -(CH2)rORb, - (CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, - (CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, - S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6-Alkyl, C1-6-Haloalkyl, -(CH2)r-3-14-gliedriger Kohlenstoffcyclus oder -(CH2)r-5-7-gliedriger Heterocyclus oder Heteroaryl, die jeweils Kohlenstoffatome und 1-4 Heteroatome umfassen, die aus N, O, und S(O)p ausgewählt sind; wobei alternativ zwei Ra an benachbarten oder demselben Kohlenstoffatom ein cyclisches Acetal der Formel -O-(CH2)n-O- oder -O-CF2-O- bilden, wobei n aus 1 oder 2 ausgewählt ist;

Rb Folgendes ist: Wasserstoff, C1-6-Alkyl, das mit 0-2 Rd substituiert ist, C1-6-Haloalkyl, C3-6-Cycloalkyl, das mit 0-2 Rd substituiert ist, oder (CH2)r-Phenyl, das mit 0-3 Rd substituiert ist;

Rc C1-6-Alkyl, C3-6-Cycloalkyl oder (CH2)r-Phenyl ist, das mit 0-3 Rf substituiert ist;

Rd Folgendes ist: Wasserstoff, F, Cl, Br, OCF3, CF3, CN, NO2, -ORe, - (CH2)rC(O)Rc, -NReRe, -NReC(O)ORc, C1-6-Alkyl oder (CH2)r-Phenyl, das mit 0-3 Rf substituiert ist;

Re Wasserstoff, C1-6-Alkyl, C3-6-Cycloalkyl oder (CH2)r-Phenyl ist, das mit 0-3 Rf substituiert ist;

Rf Wasserstoff, Halogen, NH2, OH oder O(C1-6-Alkyl) ist;

r 0, 1, 2, 3 oder 4 ist; und

p 0, 1 oder 2 ist.


 
7. Verbindung nach einem der Ansprüche 1-2 oder 4-6 oder ein Stereoisomer oder ein pharmazeutisch akzeptables Salz davon, wobei R2 aus Folgendem ausgewählt wird:













wobei jede Gruppe durch 0-4 R2a substituiert wird.
 
8. Verbindung nach einem der Ansprüche 1-7 oder ein Stereoisomer oder ein pharmazeutisch akzeptables Salz davon, wobei R2 aus Folgendem ausgewählt wird:

wobei jede Gruppe optional durch 0-3 R2a substituiert wird.
 
9. Verbindung nach einem der Ansprüche 1-7 oder ein Stereoisomer oder pharmazeutisch akzeptables Salz davon, wobei R2 aus

ausgewählt wird, wobei jede Gruppe optional durch 0-3 R2a substituiert wird.
 
10. Verbindung nach einem der Ansprüche 1-7 oder ein Stereoisomer oder ein pharmazeutisch akzeptables Salz davon wobei R2

ist und Y Cl, F, Br, CN, - OC1-6-Alkyl, C1-6-Alkyl, -HalogenC1-6-Alkyl oder NH2 ist.
 
11. Verbindung nach einem der Ansprüche 1-8 oder ein Stereoisomer oder ein pharmazeutisch akzeptables Salz davon, wobei R aus folgenden Gruppen ausgewählt wird:


























 
12. Verbindung nach einem der Ansprüche 1-11 oder ein Stereoisomer oder ein pharmazeutisch akzeptables Salz davon wobei X2 N ist und X1 CR ist; und R Wasserstoff oder C1-6-Alkyl ist.
 
13. Verbindung nach einem der Ansprüche 1-12 oder ein Stereoisomer oder ein pharmazeutisch akzeptables Salz davon, wobei R3 C1-6-Alkyl ist, das mit 0-3 R3a substituiert ist, oder Phenyl ist, das optional mit 0-3 R3a substituiert ist.
 
14. Verbindung nach einem der Ansprüche 1-13, wobei die Verbindung


 
15. Pharmazeutische Zusammensetzung, die eine Verbindung nach einem der Ansprüche 1-14 und einen pharmazeutisch annehmbaren Träger oder ein pharmazeutisch annehmbares Verdünnungsmittel umfasst.
 
16. Verbindung nach einem der Ansprüche 1-14 zur Verwendung als Medikament.
 
17. Verbindung nach einem der Ansprüche 1-14 zur Verwendung bei der Behandlung einer Entzündungs- oder Autoimmunkrankheit.
 


Revendications

1. Composé selon la formule (I):

ou un stéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci, dans lequel

A est un triazole optionnellement substitué par 0-2 R;

R est un hydrogène, R1, halogène, cyano, nitro, -OR1, -C(=O)-R1, -C(=O)O-R1, - C(=O)NR11-R1, -S(=O)2-R1, -NR11C(=O)-R1, -NR11C(=O)NR11R1, -NR11C(=O)O-R1, - NR11S(=O)2R1 ou -NR11R1 ou bien est sélectionné parmi les groupes suivants:

























R1 est un C1-6 alkyle substitué par 0-4 R1a, C1-6 haloalkyle, C2-6 alcényle substitué par 0-3 R1a, C2-6 alcynyle substitué par 0-3 R1a, C3-10 cycloalkyle substitué par 0-3 R1a, C6-10 aryle substitué par 0-3 R1a, un hétérocycle à 5-10 chaînons contenant 1-4 hétéroatomes sélectionnés parmi N, O et S, substitué par 0-3 R1a, ou bien un hétéroaryle à 5-10 chaînons contenant 1-4 hétéroatomes sélectionnés parmi N, O et S, substitué par 0-3 R1a;

R1a est un hydrogène, =O, F, Cl, Br, OCF3, CN, NO2, -(CH2)rORb, -(CH2)rSRb, - (CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, - NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyle substitué par 0-2 Ra, C1-6 haloalkyle, -(CH2)r-carbocycle à 3-14 chaînons substitué par 0-3 Ra, ou bien un -(CH2)r-hétérocycle ou hétéroaryle à 5-7 chaînons, comprenant chacun des atomes de carbone et 1-4 hétéroatomes sélectionnés parmi N, O et S(O)p substitué par 0-3 Ra;

R2 est un C6-10 aryle substitué par 0-4 R2a, un hétérocycle à 5-10 chaînons contenant 1-4 hétéroatomes sélectionnés parmi N, O et S, substitué par 1-4 R2a, ou bien un hétéroaryle à 5-10 chaînons contenant 1-4 hétéroatomes sélectionnés parmi N, O et S, substitué par 0-4 R2a;

R2a est sélectionné indépendamment à chaque occurrence parmi hydrogène, =O, halo, OCF3, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, - (CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, - (CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, -NRbS(O)pRc, -S(O)Rc, - S(O)2Rc, C1-6 alkyle substitué par 0-2 Ra, C1-6 haloalkyle, -(CH2)r-carbocycle à 3-14 chaînons substitué par 0-1 Ra, ou bien un -(CH2)r-hétérocycle ou hétéroaryle à 5-7 chaînons comprenant chacun des atomes de carbone et 1-4 hétéroatomes sélectionnés parmi N, O et S(O)P substitué par 0-2 Ra;

R3 est un C1-6 alkyle substitué par 0-3 R3a, C1-6 haloalkyle, C2-6 alcényle substitué par 0-3 R3a, C2-6 alcynyle substitué par 0-3 R3a, C3-10 cycloalkyle substitué par 0-3 R3a, C6-10 aryle substitué par 0-3 R3a, un hétérocycle de 5 à 10 chaînons contenant 1-4 hétéroatomes sélectionnés parmi N, O, et S substitué par 0-3 R3a ou bien un hétéroaryle à 5-10 chaînons contenant 1-4 hétéroatomes sélectionnés parmi N, O et S, substitué par 0-3 R3a;

R3a est un hydrogène, =O, F, Cl, Br, OCF3, CN, NO2, -(CH2)rORb, -(CH2)rSRb, - (CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, - NRbS(O)PRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyle substitué par 0-2 Ra, C1-6 haloalkyle, -(CH2)r-carbocycle à 3-14 chaînons substitué par 0-1 Ra, ou bien un -(CH2)r-hétérocycle ou hétéroaryle à 5-7 chaînons, comprenant chacun des atomes de carbone et 1-4 hétéroatomes sélectionnés parmi N, O et S(O)p substitué par 0-1 Ra;

R4 et R5 sont sélectionnés indépendamment parmi hydrogène, C1-4 alkyle substitué par 0-1 Rf, (CH2)-phényle substitué par 0-3 Rd, et -(CH2)-hétérocycle à 5-7 chaînons comprenant des atomes de carbone et 1-4 hétéroatomes sélectionnés parmi N, O et S(O)p;

R6 est sélectionné parmi hydrogène, =O, F, Cl, Br, OCF3, CN, NO2, -(CH2)rORb,-(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, - (CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, - S(O)pNR11R11, -NRbS(O)PRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyle substitué par 0-2 Ra, C1-6 haloalkyle, -(CH2)r-carbocycle à 3-14 chaînons substitué par 0-3 Ra, ou bien un -(CH2)r-hétérocycle ou hétéroaryle à 5-7 chaînons, comprenant chacun des atomes de carbone et 1-4 hétéroatomes sélectionnés parmi N, O et S(O)p substitué par 0-3 Ra;

R11 est indépendamment à chaque occurrence un hydrogène, Re, C1-4 alkyle substitué par 0-1 Rf, CH2-phényle substitué par 0-3 Rd, ou bien un -(CH2)-hétérocycle à 5-7 chaînons comprenant des atomes de carbone et 1-4 hétéroatomes sélectionnés parmi N, O et S(O)p substitué par 0-3 Rd; ou bien

R11 et un autre R11 ou R1 sur le même atome d'azote peuvent se joindre pour former un hétérocycle;

Ra est un hydrogène, F, Cl, Br, OCF3, CF3, CHF2, CN, NO2, -(CH2)rORb, - (CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, - (CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, - S(O)pNR11R11, -NRbS(O)PRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyle substitué par 0-1 Rf, C1-6 haloalkyle, -(CH2)r-carbocycle à 3-14 chaînons, ou bien un -(CH2)r-hétérocycle ou hétéroaryle à 5-7 chaînons, comprenant chacun des atomes de carbone et 1-4 hétéroatomes sélectionnés parmi N, O et S(O)p; ou bien deux Ra sur un atome de carbone adjacent ou sur le même atome de carbone forment un acétal cyclique de la formule -O-(CH2)n-O-, ou -O-CF2-O-, où n est sélectionné parmi 1 ou 2;

Rb est un hydrogène, Re, C1-6 alkyle substitué par 0-2 Rd, C1-6 haloalkyle, C3-6 cycloalkyle substitué par 0-2 Rd, ou bien un (CH2)r-phényle substitué par 0-3 Rd;

Rc est un C1-6 alkyle substitué par 0-1 Rf, C3-6 cycloalkyle ou (CH2)r-phényle substitué par 0-3 Rf;

Rd est un hydrogène, F, Cl, Br, OCF3, CF3, CN, NO2, -ORe, -(CH2)rC(O)Rc, - NReRe, -NReC(O)ORc, C1-6 alkyle ou (CH2)r-phényle substitué par 0-3 Rf;

Re est sélectionné parmi hydrogène, C1-6 alkyle, C3-6 cycloalkyle et (CH2)r-phényle substitué par 0-3 Rf;

Rf est un hydrogène, halo, NH2, OH ou O(C1-6 alkyle);

p est 0, 1 ou 2;

r est 0, 1, 2, 3 ou 4; et

m est 0, 1 ou 2.


 
2. Composé selon la revendication 1, ou un stéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci, dans lequel A est

et X1 et X2 sont sélectionnés indépendamment parmi N ou C-R, à condition que l'un d'entre X1 et X2 soit sélectionné parmi N et l'autre parmi C-R.
 
3. Composé selon l'une quelconque des revendications 1-2, ou un sel pharmaceutiquement acceptable de celui-ci, dans lequel R2 est un phényle, pyridyle, pyrimidinyle, naphtyle, indolinyle, benzothiazolyle, pyrazolopyridinyle, benzoisothiazolyle, triazolopyridinyle, imidazopyridinyle, benzooxazolyle, triazolopyridinyle, imidazopyridinyle, pyridopyrazinyle, quinazolinyle, pyridopyrazinyle, benzooxodiazolyle, benzothiadiazolyle, benzoimidazolyle, triazolopyridinyle, imidazopyridazinyle, pyridopyrazinyle, naphtyridinyle, quinoxalinyle, phtalazinyle, quinolinyle, indolyle, benzothiazolyle, benzodioxolyle, benzothiényle, isoquinolinyle, benzopyranyle, indolizinyle, benzofuranyle, chromonyle, coumarinyle, benzopyranyle, cinnolinyle, pyrrolopyridyle, furopyridyle, isoindolyle ou quinazolinyle, chaque groupe étant substitué par 1-4 groupes sélectionnés parmi R2a.
 
4. Composé selon l'une quelconque des revendications 1-3, ou un stéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci, dans lequel m est 0.
 
5. Composé selon l'une quelconque des revendications 1-4, ou un stéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci, dans lequel R4 et R5 sont tous les deux un hydrogène.
 
6. Composé selon l'une quelconque des revendications 1-5 ayant la formule suivante

ou un stéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci, dans lequel:

X1 et X2 sont sélectionnés indépendamment parmi N ou C-R, à condition que l'un d'entre X1 et X2 soit sélectionné parmi N et l'autre parmi C-R;

R est un hydrogène, R1, halogène, -C(=O)-R1, -C(=O)OR1, -C(=O)NR11R1 ou NR11R1;

R1 est un C1-6 alkyle substitué par 0-4 R1a, C1-6 haloalkyle, C2-6 alcényle substitué par 0-3 R1a, C2-6 alcynyle substitué par 0-3 R1a, C3-10 cycloalkyle substitué par 0-3 R1a, C6-10 aryle substitué par 0-3 R1a, un hétérocycle à 5-10 chaînons contenant 1-4 hétéroatomes sélectionnés parmi N, O et S, substitué par 0-3 R1a, ou bien un hétéroaryle à 5-10 chaînons contenant 1-4 hétéroatomes sélectionnés parmi N, O et S, substitué par 0-3 R1a;

R1a est un hydrogène, =O, F, Cl, Br, OCF3, CN, NO2, -(CH2)rORb, -(CH2)rSRb, - (CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11, - NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyle substitué par 0-2 Ra, C1-6 haloalkyle, -(CH2)r-carbocycle à 3-14 chaînons substitué par 0-1 Ra, ou bien un -(CH2)r-hétérocycle à 5-7 chaînons, comprenant des atomes de carbone et 1-4 hétéroatomes sélectionnés parmi N, O et S(O)p substitué par 0-1 Ra;

R2 est un phényle, pyridyle, pyrimidinyle, naphtyle, indolinyle, benzothiazolyle, pyrazolopyridinyle, benzoisothiazolyle, triazolopyridinyle, imidazopyridinyle, benzooxazolyle, triazolopyridinyle, imidazopyridinyle, pyridopyrazinyle, quinazolinyle, pyridopyrazinyle, benzooxodiazolyle, benzothiadiazolyle, benzoimidazolyle, triazolopyridinyle, imidazopyridazinyle, pyridopyrazinyle, naphtyridinyle, quinoxalinyle, phtalazinyle, quinolinyle, indolyle, benzothiazolyle, benzodioxolyle, benzothiényle, isoquinolinyle, benzopyranyle, indolizinyle, benzofuranyle, chromonyle, coumarinyle, benzopyranyle, cinnolinyle, pyrrolopyridyle, furopyridyle, isoindolyle ou quinazolinyle, chaque groupe substitué par 1-4 groupes sélectionnés parmi R2a;

R2a est un hydrogène, =O, F, Cl, Br, OCF3, CN, NO2, -(CH2)rORb, -(CH2)rSRb,-(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11, -S(O)pNR11R11,-NRbS(O)pRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyle substitué par 0-2 Ra, C1-6 haloalkyle, -(CH2)r-carbocycle à 3-14 chaînons substitué par 0-1 Ra, ou bien un -(CH2)r-hétérocycle à 5-7 chaînons comprenant des atomes de carbone et 1-4 hétéroatomes sélectionnés parmi N, O et S(O)P substitué par 0-1 Ra;

R3 est un C1-6 alkyle substitué par 0-3 R3a; ou un cycle C3-7 cycloalkyle, phényle, tétrahydropyranyle, tétrahydrofuranyle ou oxétane, chaque cycle optionnellement substitué par 0-3 R3a;

R3a est un hydrogène, =O, Cl, Br, OCF3, CF3, CHF2, CN, NO2, -(CH2)rORb,-(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11,-(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11,-S(O)pNR11R11, -NRbS(O)PRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyle substitué par 0-2 Ra, C1-6 haloalkyle, -(CH2)r-carbocycle à 3-14 chaînons substitué par 0-1 Ra, ou bien un -(CH2)r-hétérocycle à 5-7 chaînons, comprenant des atomes de carbone et 1-4 hétéroatomes sélectionnés parmi N, O et S(O)p substitué par 0-1 Ra;

R11 est indépendamment à chaque occurrence un hydrogène, C1-4 alkyle substitué par 0-1 Rf, CH2-phényle substitué par 0-3 Rd, ou bien un -(CH2)-hétérocycle à 5-7 chaînons comprenant des atomes de carbone et 1-4 hétéroatomes sélectionnés parmi N, O et S(O)p substitué par 0-3 Rd;

Ra est un hydrogène, Cl, Br, OCF3, CF3, CHF2, CN, NO2, -(CH2)rORb,-(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11,-(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRbC(O)NR11R11,-S(O)pNR11R11, -NRbS(O)PRc, -S(O)Rc, -S(O)2Rc, C1-6 alkyle, C1-6 haloalkyle, -(CH2)r-carbocycle à 3-14 chaînons, ou bien un -(CH2)r-hétérocycle ou hétéroaryle à 5-7 chaînons, comprenant chacun des atomes de carbone et 1-4 hétéroatomes sélectionnés parmi N, O et S(O)p; alternativement deux Ra sur un atome de carbone adjacent ou sur le même atome de carbone forment un acétal cyclique de la formule -O-(CH2)a-O-, ou -O-CF2-O-, où n est sélectionné parmi 1 ou 2;

Rb est un hydrogène, C1-6 alkyle substitué par 0-2 Rd, C1-6 haloalkyle, C3-6 cycloalkyle substitué par 0-2 Rd, ou bien un (CH2)r-phényle substitué par 0-3 Rd;

Rc est un C1-6 alkyle, C3-6 cycloalkyle ou (CH2)r-phényle substitué par 0-3 Rf;

Rd est un hydrogène, F, Cl, Br, OCF3, CF3, CN, NO2, -ORe, -(CH2)rC(O)Rc,-NReRe, -NReC(O)ORc, C1-6 alkyle ou (CH2)r-phényle substitué par 0-3 Rf;

Re est un hydrogène, C1-6 alkyle, C3-6 cycloalkyle ou (CH2)r-phényle substitué par 0-3 Rf;

Rf est un hydrogène, halo, NH2, OH ou O(C1-6 alkyle);

r est 0, 1, 2, 3 ou 4; et

p est 0, 1 ou 2.


 
7. Composé selon l'une quelconque des revendications 1-2 ou 4-6, ou un stéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci, dans lequel R2 est sélectionné parmi













chaque groupe étant substitué par 0-4 R2a.
 
8. Composé selon l'une quelconque des revendications 1-7, ou un stéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci, dans lequel R2 est sélectionné parmi

chaque groupe étant optionnellement substitué par 0-3 R2a.
 
9. Composé selon l'une quelconque des revendications 1-7, ou un stéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci, dans lequel R2 est sélectionné parmi

chaque groupe étant substitué par 0-3 R2a.
 
10. Composé selon l'une quelconque des revendications 1-7, ou un stéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci, dans lequel R2 est

et Y est Cl, F, Br, CN, -OC1-6 alkyle, C1-6 alkyle, -haloC1-6 alkyle ou NH2.
 
11. Composé selon l'une quelconque des revendications 1-8, ou un stéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci, dans lequel R est sélectionné parmi les groupes suivants:


























 
12. Composé selon l'une quelconque des revendications 1-11, ou un stéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci, dans lequel X2 est N et X2 est CR; et R est un hydrogène ou un C1-6 alkyle.
 
13. Composé selon l'une quelconque des revendications 1-12, ou un stéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci, dans lequel R3 est un C1-6 alkyle substitué par 0-3 R3a ou un phényle optionnellement substitué par 0-3 R3a.
 
14. Composé selon l'une quelconque des revendications 1-13, où le composé est


 
15. Composition pharmaceutique comprenant un composé selon l'une quelconque des revendications 1-14 et un véhicule ou un diluant pharmaceutiquement acceptable.
 
16. Composé selon l'une quelconque des revendications 1-14, à utiliser en tant que médicament.
 
17. Composé selon l'une quelconque des revendications 1-14, à utiliser dans le traitement d'une maladie inflammatoire ou auto-immune.
 




REFERENCES CITED IN THE DESCRIPTION



This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description




Non-patent literature cited in the description